<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235949</url>
  </required_header>
  <id_info>
    <org_study_id>112921</org_study_id>
    <secondary_id>2010-019761-28</secondary_id>
    <nct_id>NCT01235949</nct_id>
  </id_info>
  <brief_title>Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment</brief_title>
  <official_title>Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of the current study is to determine whether ibuprofen, given as immediate or delayed
      prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune
      response in children receiving primary vaccination with GlaxoSmithKline (GSK) Biologicals'
      10-valent pneumococcal conjugate vaccine, co-administered with DTPa-combined vaccines, at 3,
      4 and 5 months of age.

      In addition, this study will further evaluate the impact of prophylactic administration of
      paracetamol following primary vaccination with immediate or delayed administration or when
      given in an immediate manner at the time of the booster dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2010</start_date>
  <completion_date type="Actual">December 8, 2012</completion_date>
  <primary_completion_date type="Actual">March 28, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes Greater Than or Equal to (≥) the Cut-off</measure>
    <time_frame>One month after primary immunization (At Month 3)</time_frame>
    <description>Antibodies against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) have been assessed by 22F-inhibition enzyme-linked immunosorbent assay (ELISA). The cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.2 micrograms per milliliter (μg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Concentrations Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (At Month 3)</time_frame>
    <description>Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Concentrations Against Protein D (Anti-PD)</measure>
    <time_frame>One month after primary immunization (At Month 3)</time_frame>
    <description>Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units (EL.U) per milliliter (EL.U/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 100 EL.U/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A</measure>
    <time_frame>One month after primary immunization (At Month 3)</time_frame>
    <description>Anti-pneumococcal serotype 6A and 19A antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within the 4-day (Days 0-3) period following booster vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses</time_frame>
    <description>Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (&gt;) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within the 4-day (Days 0-3) period following booster vaccination</time_frame>
    <description>Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (&gt;) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (Month 0 to 10)</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 31-days (Day 0-30) following each primary vaccination dose</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 31-days (Day 0-30) following booster vaccination</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Anti- pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (Month 3)</time_frame>
    <description>OPA titers against pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was an antibody titer ≥ 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>OPA titers against pneumococcal serotypes (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was ≥ 8. When the number of subjects in a group for a specific category equals (=) 1, the lower limit and upper limit of the confidence interval that can't be calculated, are filled in with the GMT value (due to system constraint). Placeholder value &quot;99999.9&quot; has been entered when value to be entered in the system was greater than (&gt;) 1.0 E10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Protein D (Anti-PD)</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U//mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 100 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Diphtheria (D) and Tetanus (T) Toxoids</measure>
    <time_frame>One month after primary immunization (Month 3)</time_frame>
    <description>Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Diphteria (D) and Tetanus (T) Toxoids</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in IU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)</measure>
    <time_frame>One month after primary immunization (Month 3)</time_frame>
    <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Hepatitis B Surface Antigen (HBs)</measure>
    <time_frame>One month after primary immunization (Month 3)</time_frame>
    <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Hepatitis B Surface Antigen</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)</measure>
    <time_frame>One month after primary immunization (Month 3)</time_frame>
    <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in µg/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Poliovirus Type 1, 2 and 3</measure>
    <time_frame>One month after primary immunization (Month 3)</time_frame>
    <description>Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Poliovirus Type 1, 2 and 3</measure>
    <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
    <description>Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8.</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">850</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Group IIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DIBU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NIBU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IPARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DPARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NPARA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIBU-IIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIBU-DIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIBU-NIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DIBU-IIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DIBU-DIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DIBU-NIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NIBU-IIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NIBU-DIBU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NIBU-NIBU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IPARA-NPARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DPARA-IPARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NPARA-IPARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK1024850A (SynflorixTM)</intervention_name>
    <description>Intramuscular injection, 4 doses</description>
    <arm_group_label>Group DIBU</arm_group_label>
    <arm_group_label>Group DIBU-DIBU</arm_group_label>
    <arm_group_label>Group DIBU-IIBU</arm_group_label>
    <arm_group_label>Group DIBU-NIBU</arm_group_label>
    <arm_group_label>Group DPARA</arm_group_label>
    <arm_group_label>Group DPARA-IPARA</arm_group_label>
    <arm_group_label>Group IIBU</arm_group_label>
    <arm_group_label>Group IIBU-DIBU</arm_group_label>
    <arm_group_label>Group IIBU-IIBU</arm_group_label>
    <arm_group_label>Group IIBU-NIBU</arm_group_label>
    <arm_group_label>Group IPARA</arm_group_label>
    <arm_group_label>Group IPARA-NPARA</arm_group_label>
    <arm_group_label>Group NIBU</arm_group_label>
    <arm_group_label>Group NIBU-DIBU</arm_group_label>
    <arm_group_label>Group NIBU-IIBU</arm_group_label>
    <arm_group_label>Group NIBU-NIBU</arm_group_label>
    <arm_group_label>Group NPARA</arm_group_label>
    <arm_group_label>Group NPARA-IPARA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Group DIBU</arm_group_label>
    <arm_group_label>Group DIBU-DIBU</arm_group_label>
    <arm_group_label>Group DIBU-IIBU</arm_group_label>
    <arm_group_label>Group DIBU-NIBU</arm_group_label>
    <arm_group_label>Group DPARA</arm_group_label>
    <arm_group_label>Group DPARA-IPARA</arm_group_label>
    <arm_group_label>Group IIBU</arm_group_label>
    <arm_group_label>Group IIBU-DIBU</arm_group_label>
    <arm_group_label>Group IIBU-IIBU</arm_group_label>
    <arm_group_label>Group IIBU-NIBU</arm_group_label>
    <arm_group_label>Group IPARA</arm_group_label>
    <arm_group_label>Group IPARA-NPARA</arm_group_label>
    <arm_group_label>Group NIBU</arm_group_label>
    <arm_group_label>Group NIBU-DIBU</arm_group_label>
    <arm_group_label>Group NIBU-IIBU</arm_group_label>
    <arm_group_label>Group NIBU-NIBU</arm_group_label>
    <arm_group_label>Group NPARA</arm_group_label>
    <arm_group_label>Group NPARA-IPARA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix-IPV/Hib</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Group DIBU</arm_group_label>
    <arm_group_label>Group DIBU-DIBU</arm_group_label>
    <arm_group_label>Group DIBU-IIBU</arm_group_label>
    <arm_group_label>Group DIBU-NIBU</arm_group_label>
    <arm_group_label>Group DPARA</arm_group_label>
    <arm_group_label>Group DPARA-IPARA</arm_group_label>
    <arm_group_label>Group IIBU</arm_group_label>
    <arm_group_label>Group IIBU-DIBU</arm_group_label>
    <arm_group_label>Group IIBU-IIBU</arm_group_label>
    <arm_group_label>Group IIBU-NIBU</arm_group_label>
    <arm_group_label>Group IPARA</arm_group_label>
    <arm_group_label>Group IPARA-NPARA</arm_group_label>
    <arm_group_label>Group NIBU</arm_group_label>
    <arm_group_label>Group NIBU-DIBU</arm_group_label>
    <arm_group_label>Group NIBU-IIBU</arm_group_label>
    <arm_group_label>Group NIBU-NIBU</arm_group_label>
    <arm_group_label>Group NPARA</arm_group_label>
    <arm_group_label>Group NPARA-IPARA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight</description>
    <arm_group_label>Group DIBU</arm_group_label>
    <arm_group_label>Group DIBU-DIBU</arm_group_label>
    <arm_group_label>Group DIBU-IIBU</arm_group_label>
    <arm_group_label>Group IIBU</arm_group_label>
    <arm_group_label>Group IIBU-IIBU</arm_group_label>
    <arm_group_label>Group IIBU-NIBU</arm_group_label>
    <arm_group_label>Group NIBU-DIBU</arm_group_label>
    <arm_group_label>Group NIBU-IIBU</arm_group_label>
    <other_name>Nurofen for Children</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight</description>
    <arm_group_label>Group DPARA</arm_group_label>
    <arm_group_label>Group DPARA-IPARA</arm_group_label>
    <arm_group_label>Group IPARA</arm_group_label>
    <arm_group_label>Group NPARA-IPARA</arm_group_label>
    <other_name>Panadol Baby</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LAR) can and will comply with the requirements of the protocol.

          -  A male or female between, and including, 12 and 16 weeks (84-118 days) of age at the
             time of the first vaccination.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Born after a gestation period of 36 to 42 weeks inclusive.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study
             vaccines/products within 30 days preceding the first dose of study vaccine/product, or
             planned use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (.

          -  Indication, other than specified in the protocol, for prophylactic or therapeutic
             antipyretic treatment during the study period.

          -  Treatment with antipyretics in the 24 hours before study vaccination or planned
             administration of antipyretics in the 24 hours after study vaccination.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             during the period starting 30 days before each dose of study vaccine and ending 30
             days after with the exception of locally recommended (pandemic) influenza vaccines,
             and those should be documented in the eCRF.

          -  Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B,
             Haemophilus influenzae type b and/or Streptococcus pneumoniae with the exception of
             the vaccines where the first dose may be given within the first two weeks of life
             according to the national recommendations.

          -  History of intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B,
             Haemophilus influenzae type b disease.

          -  History of any allergic disease or reaction likely to be exacerbated by any component
             of the vaccines or prophylactic antipyretic treatment, i.e. ibuprofen or paracetamol,
             as specified in the protocol.

          -  History of any seizures or progressive neurological disease.

          -  Acute disease and/or fever at the time of enrolment. The study entry should be delayed
             until the illness has improved.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination .

          -  A family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during entire study period.

          -  Any contraindication to treatment with ibuprofen as described in the ibuprofen summary
             of product characteristics (SPC).

          -  Any contraindication to treatment with paracetamol as described in the paracetamol
             SPC.

          -  Body weight &lt; 5 kg at the time of enrolment.

          -  Child in care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Weeks</minimum_age>
    <maximum_age>16 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bacau</city>
        <zip>600316</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810289</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810346</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500063</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500260</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500366</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>051821</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>077190</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>030442</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>050734</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calarasi</city>
        <zip>910160</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400217</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900709</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900721</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800099</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800179</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800235</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800322</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800394</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pantelimon</city>
        <zip>77145</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300593</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Falup-Pecurariu O, Man SC, Neamtu ML, Chicin G, Baciu G, Pitic C, Cara AC, Neculau AE, Burlea M, Brinza IL, Schnell CN, Sas V, Lupu VV, François N, Swinnen K, Borys D. Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial. Hum Vaccin Immunother. 2017 Mar 4;13(3):649-660. doi: 10.1080/21645515.2016.1223001. Epub 2016 Aug 19.</citation>
    <PMID>27541270</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2010</study_first_posted>
  <results_first_submitted>September 29, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2019</results_first_posted>
  <disposition_first_submitted>April 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 18, 2013</disposition_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Fever</keyword>
  <keyword>Primary vaccination</keyword>
  <keyword>Booster vaccination</keyword>
  <keyword>Pneumococcal disease</keyword>
  <keyword>Prophylactic antipyretic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112921</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112921</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112921</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112921</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112921</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112921</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Among the 850 subjects enrolled in the study, 35 subjects were excluded for lack of confidence in the integrity of the data and 3 subjects were allocated with subject number but didn't receive any vaccination.</recruitment_details>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
        </group>
        <group group_id="P2">
          <title>DIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="P3">
          <title>NIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="P4">
          <title>IPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="P5">
          <title>DPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="P6">
          <title>NPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="P7">
          <title>IIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P8">
          <title>IIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P9">
          <title>IIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P10">
          <title>DIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P11">
          <title>DIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P12">
          <title>DIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P13">
          <title>NIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P14">
          <title>NIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P15">
          <title>NIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P16">
          <title>IPARA-NPARA Group</title>
          <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P17">
          <title>DPARA-IPARA Group</title>
          <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="P18">
          <title>NPARA-IPARA Group</title>
          <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="199"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="72"/>
                <participants group_id="P6" count="74"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194">After Primary Phase completion, 7 subjects were not willing to participate in the Booster Phase</participants>
                <participants group_id="P2" count="195">After Primary Phase completion, 6 subjects were not willing to participate in the Booster Phase</participants>
                <participants group_id="P3" count="196">After Primary Phase completion, 6 subjects were not willing to participate in the Booster Phase</participants>
                <participants group_id="P4" count="69">After Primary Phase completion, 2 subjects were not willing to participate in the Booster Phase</participants>
                <participants group_id="P5" count="71">After Primary Phase completion, 3 subjects were not willing to participate in the Booster Phase</participants>
                <participants group_id="P6" count="67">After Primary Phase completion, all subjects were willing to participate in the Booster Phase</participants>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">re-randomized to diverse treatments (IIBU-IIBU, IIBU-DIBU and IIBU-NIBU Groups) in booster phase</participants>
                <participants group_id="P2" count="0">re-randomized to diverse treatments (DIBU-IIBU, DIBU-DIBU and DIBU-NIBU Groups) in booster phase</participants>
                <participants group_id="P3" count="0">re-randomized to diverse treatments (NIBU-IIBU, NIBU-DIBU and NIBU-NIBU Groups) in booster phase</participants>
                <participants group_id="P4" count="0">subjects re-randomized to IPARA-NPARA Group in booster phase</participants>
                <participants group_id="P5" count="0">subjects re-randomized to DPARA-IPARA Group in booster phase</participants>
                <participants group_id="P6" count="0">subjects re-randomized to NPARA-IPARA Group in booster phase</participants>
                <participants group_id="P7" count="64">1/3 of subjects from primary IIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P8" count="60">1/3 of subjects from primary IIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P9" count="63">1/3 of subjects from primary IIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P10" count="63">1/3 of subjects from primary DIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P11" count="63">1/3 of subjects from primary DIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P12" count="63">1/3 of subjects from primary DIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P13" count="63">1/3 of subjects from primary NIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P14" count="65">1/3 of subjects from primary NIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P15" count="62">1/3 of subjects from primary NIBU group re-randomized to receive diverse booster phase treatments</participants>
                <participants group_id="P16" count="67">subjects from the primary IPARA group continuing in booster phase with different treatment</participants>
                <participants group_id="P17" count="68">subjects from the primary DPARA group continuing in booster phase with different treatment</participants>
                <participants group_id="P18" count="67">subjects from the primary NPARA group continuing in booster phase with different treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="64"/>
                <participants group_id="P8" count="59"/>
                <participants group_id="P9" count="61"/>
                <participants group_id="P10" count="62"/>
                <participants group_id="P11" count="61"/>
                <participants group_id="P12" count="60"/>
                <participants group_id="P13" count="60"/>
                <participants group_id="P14" count="65"/>
                <participants group_id="P15" count="60"/>
                <participants group_id="P16" count="66"/>
                <participants group_id="P17" count="68"/>
                <participants group_id="P18" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
        </group>
        <group group_id="B2">
          <title>DIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="B3">
          <title>NIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="B4">
          <title>IPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="B5">
          <title>DPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="B6">
          <title>NPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="B7">
          <title>IIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B8">
          <title>IIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B9">
          <title>IIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B10">
          <title>DIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B11">
          <title>DIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B12">
          <title>DIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B13">
          <title>NIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B14">
          <title>NIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B15">
          <title>NIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B16">
          <title>IPARA-NPARA Group</title>
          <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B17">
          <title>DPARA-IPARA Group</title>
          <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B18">
          <title>NPARA-IPARA Group</title>
          <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="199"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="72"/>
            <count group_id="B6" value="74"/>
            <count group_id="B7" value="64"/>
            <count group_id="B8" value="60"/>
            <count group_id="B9" value="63"/>
            <count group_id="B10" value="63"/>
            <count group_id="B11" value="63"/>
            <count group_id="B12" value="63"/>
            <count group_id="B13" value="63"/>
            <count group_id="B14" value="65"/>
            <count group_id="B15" value="62"/>
            <count group_id="B16" value="67"/>
            <count group_id="B17" value="68"/>
            <count group_id="B18" value="67"/>
            <count group_id="B19" value="1580"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Primary Phase Groups</description>
          <population>This baseline measure refers only to the primary phase groups.</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="198"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="199"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="72"/>
                    <count group_id="B6" value="74"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="0"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="0"/>
                    <count group_id="B19" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.1" spread="1.15"/>
                    <measurement group_id="B2" value="13" spread="1.2"/>
                    <measurement group_id="B3" value="12.9" spread="1.14"/>
                    <measurement group_id="B4" value="13" spread="1.3"/>
                    <measurement group_id="B5" value="13.2" spread="1.3"/>
                    <measurement group_id="B6" value="13.2" spread="1.11"/>
                    <measurement group_id="B19" value="13.04" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Booster Phase Groups</description>
          <population>This baseline measure refers only to the booster phase groups.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="64"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="63"/>
                    <count group_id="B10" value="63"/>
                    <count group_id="B11" value="63"/>
                    <count group_id="B12" value="63"/>
                    <count group_id="B13" value="63"/>
                    <count group_id="B14" value="65"/>
                    <count group_id="B15" value="62"/>
                    <count group_id="B16" value="67"/>
                    <count group_id="B17" value="68"/>
                    <count group_id="B18" value="67"/>
                    <count group_id="B19" value="768"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="12.3" spread="0.64"/>
                    <measurement group_id="B8" value="12.2" spread="0.49"/>
                    <measurement group_id="B9" value="12.3" spread="0.57"/>
                    <measurement group_id="B10" value="12.2" spread="0.45"/>
                    <measurement group_id="B11" value="12.4" spread="0.63"/>
                    <measurement group_id="B12" value="12.4" spread="0.73"/>
                    <measurement group_id="B13" value="12.3" spread="0.63"/>
                    <measurement group_id="B14" value="12.3" spread="0.57"/>
                    <measurement group_id="B15" value="12.3" spread="0.70"/>
                    <measurement group_id="B16" value="12.3" spread="0.73"/>
                    <measurement group_id="B17" value="12.3" spread="0.56"/>
                    <measurement group_id="B18" value="12.4" spread="0.63"/>
                    <measurement group_id="B19" value="12.3" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Primary Phase Groups</description>
          <population>This baseline measure refers only to the primary phase groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="198"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="199"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="72"/>
                    <count group_id="B6" value="74"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="0"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="0"/>
                    <count group_id="B19" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B19" value="397"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B19" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Booster Phase Groups</description>
          <population>This baseline measure refers only to the booster phase groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="64"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="63"/>
                    <count group_id="B10" value="63"/>
                    <count group_id="B11" value="63"/>
                    <count group_id="B12" value="63"/>
                    <count group_id="B13" value="63"/>
                    <count group_id="B14" value="65"/>
                    <count group_id="B15" value="62"/>
                    <count group_id="B16" value="67"/>
                    <count group_id="B17" value="68"/>
                    <count group_id="B18" value="67"/>
                    <count group_id="B19" value="768"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B7" value="29"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="29"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="33"/>
                    <measurement group_id="B12" value="27"/>
                    <measurement group_id="B13" value="32"/>
                    <measurement group_id="B14" value="35"/>
                    <measurement group_id="B15" value="35"/>
                    <measurement group_id="B16" value="37"/>
                    <measurement group_id="B17" value="39"/>
                    <measurement group_id="B18" value="33"/>
                    <measurement group_id="B19" value="379"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="33"/>
                    <measurement group_id="B9" value="34"/>
                    <measurement group_id="B10" value="40"/>
                    <measurement group_id="B11" value="30"/>
                    <measurement group_id="B12" value="36"/>
                    <measurement group_id="B13" value="31"/>
                    <measurement group_id="B14" value="30"/>
                    <measurement group_id="B15" value="27"/>
                    <measurement group_id="B16" value="30"/>
                    <measurement group_id="B17" value="29"/>
                    <measurement group_id="B18" value="34"/>
                    <measurement group_id="B19" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Primary Phase Groups</description>
          <population>This baseline measure refers only to the primary phase groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White- Caucasian/European heritage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="198"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="199"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="72"/>
                    <count group_id="B6" value="74"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="0"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="0"/>
                    <count group_id="B19" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="198"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="72"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B19" value="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="198"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="199"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="72"/>
                    <count group_id="B6" value="74"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="0"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="0"/>
                    <count group_id="B19" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B19" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="198"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="199"/>
                    <count group_id="B4" value="71"/>
                    <count group_id="B5" value="72"/>
                    <count group_id="B6" value="74"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="0"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="0"/>
                    <count group_id="B19" value="812"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B19" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Booster Phase Groups</description>
          <population>This baseline measure refers only to the booster phase groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White- Caucasian/European heritage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="64"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="63"/>
                    <count group_id="B10" value="63"/>
                    <count group_id="B11" value="63"/>
                    <count group_id="B12" value="63"/>
                    <count group_id="B13" value="63"/>
                    <count group_id="B14" value="65"/>
                    <count group_id="B15" value="62"/>
                    <count group_id="B16" value="67"/>
                    <count group_id="B17" value="68"/>
                    <count group_id="B18" value="67"/>
                    <count group_id="B19" value="768"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="64"/>
                    <measurement group_id="B8" value="60"/>
                    <measurement group_id="B9" value="63"/>
                    <measurement group_id="B10" value="63"/>
                    <measurement group_id="B11" value="63"/>
                    <measurement group_id="B12" value="62"/>
                    <measurement group_id="B13" value="63"/>
                    <measurement group_id="B14" value="65"/>
                    <measurement group_id="B15" value="62"/>
                    <measurement group_id="B16" value="66"/>
                    <measurement group_id="B17" value="68"/>
                    <measurement group_id="B18" value="66"/>
                    <measurement group_id="B19" value="765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="64"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="63"/>
                    <count group_id="B10" value="63"/>
                    <count group_id="B11" value="63"/>
                    <count group_id="B12" value="63"/>
                    <count group_id="B13" value="63"/>
                    <count group_id="B14" value="65"/>
                    <count group_id="B15" value="62"/>
                    <count group_id="B16" value="67"/>
                    <count group_id="B17" value="68"/>
                    <count group_id="B18" value="67"/>
                    <count group_id="B19" value="768"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="64"/>
                    <count group_id="B8" value="60"/>
                    <count group_id="B9" value="63"/>
                    <count group_id="B10" value="63"/>
                    <count group_id="B11" value="63"/>
                    <count group_id="B12" value="63"/>
                    <count group_id="B13" value="63"/>
                    <count group_id="B14" value="65"/>
                    <count group_id="B15" value="62"/>
                    <count group_id="B16" value="67"/>
                    <count group_id="B17" value="68"/>
                    <count group_id="B18" value="67"/>
                    <count group_id="B19" value="768"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes Greater Than or Equal to (≥) the Cut-off</title>
        <description>Antibodies against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) have been assessed by 22F-inhibition enzyme-linked immunosorbent assay (ELISA). The cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.2 micrograms per milliliter (μg/mL).</description>
        <time_frame>One month after primary immunization (At Month 3)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes Greater Than or Equal to (≥) the Cut-off</title>
          <description>Antibodies against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) have been assessed by 22F-inhibition enzyme-linked immunosorbent assay (ELISA). The cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.2 micrograms per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="158"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="133"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="164"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="55"/>
                    <measurement group_id="O6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="154"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="157"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="162"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.52</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococcal serotype 4.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: the upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0.06</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.94</ci_lower_limit>
            <ci_upper_limit>4.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 5.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 6B.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0.69</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 7F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0.65</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 9V.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>3.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 14.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.68</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 18C.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.04</ci_lower_limit>
            <ci_upper_limit>3.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 19F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>3.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 23F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus IIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0.08</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_lower_limit>-7.66</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.52</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 4.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.57</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 5.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 6B.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-2.38</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.02</ci_lower_limit>
            <ci_upper_limit>7.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 7F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.34</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 9V.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-1.27</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.66</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 14.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.08</ci_lower_limit>
            <ci_upper_limit>4.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 18C.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.08</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 19F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0.67</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL were calculated for anti-pneumococccal serotype 23F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of non-inferiority: The upper limit (UL) of the 2-sided 98.25% confidence interval (98.25% CI) (adjusted 1-sided alpha = 0.875%) of the difference between groups (NIBU minus DIBU), in terms of percentage of subjects with pneumococcal antibody concentrations ≥ 0.2 µg/mL, was lower than (&lt;) 10% for at least 7 out of the 10 pneumococcal serotypes.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>2.73</param_value>
            <ci_percent>98.25</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>11.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations Against Vaccine Pneumococcal Serotypes</title>
        <description>Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL.</description>
        <time_frame>One month after primary immunization (At Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Vaccine Pneumococcal Serotypes</title>
          <description>Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="1.59" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.49" upper_limit="1.95"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.67" upper_limit="2.17"/>
                    <measurement group_id="O4" value="1.32" lower_limit="1.04" upper_limit="1.67"/>
                    <measurement group_id="O5" value="1.38" lower_limit="1.09" upper_limit="1.74"/>
                    <measurement group_id="O6" value="1.95" lower_limit="1.64" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.97" upper_limit="2.57"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.95" upper_limit="2.51"/>
                    <measurement group_id="O3" value="2.21" lower_limit="1.96" upper_limit="2.5"/>
                    <measurement group_id="O4" value="1.57" lower_limit="1.21" upper_limit="2.04"/>
                    <measurement group_id="O5" value="1.95" lower_limit="1.63" upper_limit="2.32"/>
                    <measurement group_id="O6" value="2.59" lower_limit="2.07" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="2.58" upper_limit="3.33"/>
                    <measurement group_id="O2" value="2.39" lower_limit="2.13" upper_limit="2.69"/>
                    <measurement group_id="O3" value="2.77" lower_limit="2.44" upper_limit="3.15"/>
                    <measurement group_id="O4" value="1.95" lower_limit="1.53" upper_limit="2.48"/>
                    <measurement group_id="O5" value="2.36" lower_limit="1.89" upper_limit="2.94"/>
                    <measurement group_id="O6" value="3.05" lower_limit="2.53" upper_limit="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.55" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.76" lower_limit="0.63" upper_limit="0.92"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.49" upper_limit="0.72"/>
                    <measurement group_id="O4" value="0.49" lower_limit="0.34" upper_limit="0.69"/>
                    <measurement group_id="O5" value="0.42" lower_limit="0.28" upper_limit="0.62"/>
                    <measurement group_id="O6" value="0.72" lower_limit="0.51" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="164"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="2.52" upper_limit="3.27"/>
                    <measurement group_id="O2" value="2.83" lower_limit="2.52" upper_limit="3.17"/>
                    <measurement group_id="O3" value="2.77" lower_limit="2.49" upper_limit="3.09"/>
                    <measurement group_id="O4" value="2.18" lower_limit="1.75" upper_limit="2.7"/>
                    <measurement group_id="O5" value="2.45" lower_limit="2.01" upper_limit="2.99"/>
                    <measurement group_id="O6" value="2.95" lower_limit="2.37" upper_limit="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.81" upper_limit="2.42"/>
                    <measurement group_id="O2" value="2.01" lower_limit="1.79" upper_limit="2.27"/>
                    <measurement group_id="O3" value="2.18" lower_limit="1.91" upper_limit="2.5"/>
                    <measurement group_id="O4" value="1.67" lower_limit="1.3" upper_limit="2.13"/>
                    <measurement group_id="O5" value="1.82" lower_limit="1.48" upper_limit="2.23"/>
                    <measurement group_id="O6" value="2.4" lower_limit="1.87" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" lower_limit="4.1" upper_limit="5.51"/>
                    <measurement group_id="O2" value="4.52" lower_limit="3.91" upper_limit="5.21"/>
                    <measurement group_id="O3" value="4.77" lower_limit="4.08" upper_limit="5.58"/>
                    <measurement group_id="O4" value="3.44" lower_limit="2.55" upper_limit="4.62"/>
                    <measurement group_id="O5" value="4.12" lower_limit="3.21" upper_limit="5.29"/>
                    <measurement group_id="O6" value="5.17" lower_limit="4.2" upper_limit="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="3.23" upper_limit="4.6"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.24" upper_limit="4.46"/>
                    <measurement group_id="O3" value="4.34" lower_limit="3.65" upper_limit="5.15"/>
                    <measurement group_id="O4" value="3.08" lower_limit="2.29" upper_limit="4.15"/>
                    <measurement group_id="O5" value="4.08" lower_limit="3.15" upper_limit="5.29"/>
                    <measurement group_id="O6" value="4.96" lower_limit="3.75" upper_limit="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" lower_limit="5.26" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.04" lower_limit="4.35" upper_limit="5.86"/>
                    <measurement group_id="O3" value="4.96" lower_limit="4.22" upper_limit="5.83"/>
                    <measurement group_id="O4" value="4.95" lower_limit="3.74" upper_limit="6.54"/>
                    <measurement group_id="O5" value="5.2" lower_limit="3.94" upper_limit="6.85"/>
                    <measurement group_id="O6" value="6.98" lower_limit="5.48" upper_limit="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="162"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.86" upper_limit="1.26"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.76" upper_limit="1.11"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.91" upper_limit="1.26"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.54" upper_limit="1.09"/>
                    <measurement group_id="O5" value="0.74" lower_limit="0.51" upper_limit="1.08"/>
                    <measurement group_id="O6" value="1" lower_limit="0.73" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 4.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 5.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 6B.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 7F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 9V.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 14.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 18C.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 19F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-pneumococcal serotype 23F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 4.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 5.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 6B.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.28</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 7F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 9V.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 14.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 18C.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 19F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-pneumococcal serotype 23F.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for at least one of the 10 vaccine pneumococcal serotypes.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations Against Protein D (Anti-PD)</title>
        <description>Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units (EL.U) per milliliter (EL.U/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 100 EL.U/mL.</description>
        <time_frame>One month after primary immunization (At Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Protein D (Anti-PD)</title>
          <description>Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units (EL.U) per milliliter (EL.U/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 100 EL.U/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1461.3" lower_limit="1267.4" upper_limit="1684.8"/>
                    <measurement group_id="O2" value="1353.1" lower_limit="1191.3" upper_limit="1537"/>
                    <measurement group_id="O3" value="1557.7" lower_limit="1355.4" upper_limit="1790.3"/>
                    <measurement group_id="O4" value="1109.6" lower_limit="876.9" upper_limit="1404.1"/>
                    <measurement group_id="O5" value="1348.6" lower_limit="1048.2" upper_limit="1734.9"/>
                    <measurement group_id="O6" value="1667.9" lower_limit="1401.9" upper_limit="1984.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (IIBU over NIBU) were calculated for anti-Protein D (anti-PD) antibody.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (IIBU over NIBU) was below (&lt;) 1 for protein D.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At one month after primary immunization, ELISA Geometric Mean Concentration (GMC) ratios (DIBU over NIBU) were calculated for anti-Protein D (anti-PD) antibody.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A statistically significant decrease in GMC was established if the UL of the two-sided 99.8% CI (adjusted one-sided alpha = 0.11364%) for the GMC ratios (DIBU over NIBU) was below (&lt;) 1 for protein D.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>99.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A</title>
        <description>Anti-pneumococcal serotype 6A and 19A antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL.</description>
        <time_frame>One month after primary immunization (At Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A</title>
          <description>Anti-pneumococcal serotype 6A and 19A antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.15" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.12" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.08" upper_limit="0.16"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.08" upper_limit="0.17"/>
                    <measurement group_id="O6" value="0.19" lower_limit="0.13" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.18" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.16" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.13" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.11" upper_limit="0.22"/>
                    <measurement group_id="O5" value="0.17" lower_limit="0.12" upper_limit="0.25"/>
                    <measurement group_id="O6" value="0.25" lower_limit="0.17" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm).</description>
        <time_frame>Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm).</description>
        <time_frame>Within the 4-day (Days 0-3) period following booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="63"/>
                <count group_id="O9" value="61"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="23"/>
                    <measurement group_id="O11" value="24"/>
                    <measurement group_id="O12" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="23"/>
                    <measurement group_id="O11" value="23"/>
                    <measurement group_id="O12" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="17"/>
                    <measurement group_id="O11" value="12"/>
                    <measurement group_id="O12" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (&gt;) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (&gt;) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="123"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (&gt;) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 4-day (Days 0-3) period following booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (&gt;) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose and had the symptoms sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="63"/>
                <count group_id="O9" value="61"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="16"/>
                    <measurement group_id="O12" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="10"/>
                    <measurement group_id="O11" value="13"/>
                    <measurement group_id="O12" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="32"/>
                    <measurement group_id="O10" value="26"/>
                    <measurement group_id="O11" value="22"/>
                    <measurement group_id="O12" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="27"/>
                    <measurement group_id="O10" value="18"/>
                    <measurement group_id="O11" value="20"/>
                    <measurement group_id="O12" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="21"/>
                    <measurement group_id="O11" value="14"/>
                    <measurement group_id="O12" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="18"/>
                    <measurement group_id="O11" value="13"/>
                    <measurement group_id="O12" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity.</description>
        <time_frame>During the entire study period (Month 0 to 10)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVC), which included all vaccinated subjects who received at least one vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVC), which included all vaccinated subjects who received at least one vaccine dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 31-days (Day 0-30) following each primary vaccination dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 31-days (Day 0-30) following booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who received at least one vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="62"/>
                <count group_id="O10" value="67"/>
                <count group_id="O11" value="68"/>
                <count group_id="O12" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Vaccine Pneumococcal Serotypes</title>
        <description>Anti- pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Vaccine Pneumococcal Serotypes</title>
          <description>Anti- pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="50"/>
                <count group_id="O11" value="47"/>
                <count group_id="O12" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="44"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="48"/>
                    <count group_id="O11" value="41"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.31" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.28" upper_limit="0.46"/>
                    <measurement group_id="O3" value="0.27" lower_limit="0.22" upper_limit="0.34"/>
                    <measurement group_id="O4" value="0.38" lower_limit="0.28" upper_limit="0.53"/>
                    <measurement group_id="O5" value="0.42" lower_limit="0.31" upper_limit="0.57"/>
                    <measurement group_id="O6" value="0.34" lower_limit="0.27" upper_limit="0.42"/>
                    <measurement group_id="O7" value="0.44" lower_limit="0.34" upper_limit="0.58"/>
                    <measurement group_id="O8" value="0.38" lower_limit="0.3" upper_limit="0.48"/>
                    <measurement group_id="O9" value="0.43" lower_limit="0.32" upper_limit="0.58"/>
                    <measurement group_id="O10" value="0.31" lower_limit="0.24" upper_limit="0.4"/>
                    <measurement group_id="O11" value="0.3" lower_limit="0.23" upper_limit="0.4"/>
                    <measurement group_id="O12" value="0.45" lower_limit="0.32" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="2.1" upper_limit="3.91"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.57" upper_limit="3.17"/>
                    <measurement group_id="O3" value="2.39" lower_limit="1.68" upper_limit="3.41"/>
                    <measurement group_id="O4" value="2.69" lower_limit="1.99" upper_limit="3.63"/>
                    <measurement group_id="O5" value="2.44" lower_limit="1.78" upper_limit="3.33"/>
                    <measurement group_id="O6" value="1.87" lower_limit="1.36" upper_limit="2.57"/>
                    <measurement group_id="O7" value="2.84" lower_limit="2.02" upper_limit="3.99"/>
                    <measurement group_id="O8" value="3.04" lower_limit="2.38" upper_limit="3.88"/>
                    <measurement group_id="O9" value="2.84" lower_limit="2.1" upper_limit="3.85"/>
                    <measurement group_id="O10" value="1.76" lower_limit="1.29" upper_limit="2.38"/>
                    <measurement group_id="O11" value="2.14" lower_limit="1.59" upper_limit="2.89"/>
                    <measurement group_id="O12" value="2.84" lower_limit="2.06" upper_limit="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.55" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.5" upper_limit="0.8"/>
                    <measurement group_id="O3" value="0.55" lower_limit="0.44" upper_limit="0.69"/>
                    <measurement group_id="O4" value="0.63" lower_limit="0.47" upper_limit="0.85"/>
                    <measurement group_id="O5" value="0.72" lower_limit="0.55" upper_limit="0.95"/>
                    <measurement group_id="O6" value="0.64" lower_limit="0.49" upper_limit="0.83"/>
                    <measurement group_id="O7" value="0.72" lower_limit="0.55" upper_limit="0.93"/>
                    <measurement group_id="O8" value="0.73" lower_limit="0.55" upper_limit="0.98"/>
                    <measurement group_id="O9" value="0.62" lower_limit="0.47" upper_limit="0.82"/>
                    <measurement group_id="O10" value="0.52" lower_limit="0.39" upper_limit="0.68"/>
                    <measurement group_id="O11" value="0.6" lower_limit="0.48" upper_limit="0.76"/>
                    <measurement group_id="O12" value="0.84" lower_limit="0.64" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" lower_limit="3.2" upper_limit="5.22"/>
                    <measurement group_id="O2" value="3.65" lower_limit="2.76" upper_limit="4.84"/>
                    <measurement group_id="O3" value="3.22" lower_limit="2.36" upper_limit="4.39"/>
                    <measurement group_id="O4" value="4.05" lower_limit="2.99" upper_limit="5.5"/>
                    <measurement group_id="O5" value="3.63" lower_limit="2.84" upper_limit="4.62"/>
                    <measurement group_id="O6" value="3.41" lower_limit="2.46" upper_limit="4.71"/>
                    <measurement group_id="O7" value="4.04" lower_limit="3.05" upper_limit="5.36"/>
                    <measurement group_id="O8" value="4.08" lower_limit="3.11" upper_limit="5.36"/>
                    <measurement group_id="O9" value="4.07" lower_limit="3.09" upper_limit="5.35"/>
                    <measurement group_id="O10" value="3.27" lower_limit="2.51" upper_limit="4.25"/>
                    <measurement group_id="O11" value="3.31" lower_limit="2.66" upper_limit="4.12"/>
                    <measurement group_id="O12" value="4.28" lower_limit="3.23" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="44"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.74" upper_limit="1.29"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.66" upper_limit="1.05"/>
                    <measurement group_id="O3" value="0.76" lower_limit="0.59" upper_limit="0.98"/>
                    <measurement group_id="O4" value="0.78" lower_limit="0.61" upper_limit="1"/>
                    <measurement group_id="O5" value="0.76" lower_limit="0.58" upper_limit="0.99"/>
                    <measurement group_id="O6" value="0.7" lower_limit="0.57" upper_limit="0.86"/>
                    <measurement group_id="O7" value="0.83" lower_limit="0.66" upper_limit="1.05"/>
                    <measurement group_id="O8" value="0.84" lower_limit="0.67" upper_limit="1.04"/>
                    <measurement group_id="O9" value="0.96" lower_limit="0.76" upper_limit="1.23"/>
                    <measurement group_id="O10" value="0.59" lower_limit="0.45" upper_limit="0.77"/>
                    <measurement group_id="O11" value="0.72" lower_limit="0.57" upper_limit="0.91"/>
                    <measurement group_id="O12" value="0.85" lower_limit="0.62" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.45" upper_limit="5.88"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.95" upper_limit="5.16"/>
                    <measurement group_id="O3" value="4.11" lower_limit="2.91" upper_limit="5.81"/>
                    <measurement group_id="O4" value="3.42" lower_limit="2.62" upper_limit="4.46"/>
                    <measurement group_id="O5" value="3.33" lower_limit="2.56" upper_limit="4.33"/>
                    <measurement group_id="O6" value="3.37" lower_limit="2.46" upper_limit="4.6"/>
                    <measurement group_id="O7" value="4.21" lower_limit="3.03" upper_limit="5.86"/>
                    <measurement group_id="O8" value="3.92" lower_limit="3.06" upper_limit="5.01"/>
                    <measurement group_id="O9" value="4.48" lower_limit="3.48" upper_limit="5.77"/>
                    <measurement group_id="O10" value="2.62" lower_limit="1.92" upper_limit="3.57"/>
                    <measurement group_id="O11" value="3.58" lower_limit="2.74" upper_limit="4.69"/>
                    <measurement group_id="O12" value="4.33" lower_limit="3.26" upper_limit="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="50"/>
                    <count group_id="O11" value="47"/>
                    <count group_id="O12" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.48" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.44" lower_limit="0.31" upper_limit="0.61"/>
                    <measurement group_id="O3" value="0.54" lower_limit="0.4" upper_limit="0.72"/>
                    <measurement group_id="O4" value="0.55" lower_limit="0.4" upper_limit="0.77"/>
                    <measurement group_id="O5" value="0.62" lower_limit="0.48" upper_limit="0.8"/>
                    <measurement group_id="O6" value="0.6" lower_limit="0.45" upper_limit="0.8"/>
                    <measurement group_id="O7" value="0.56" lower_limit="0.42" upper_limit="0.75"/>
                    <measurement group_id="O8" value="0.58" lower_limit="0.43" upper_limit="0.78"/>
                    <measurement group_id="O9" value="0.67" lower_limit="0.51" upper_limit="0.87"/>
                    <measurement group_id="O10" value="0.43" lower_limit="0.33" upper_limit="0.56"/>
                    <measurement group_id="O11" value="0.43" lower_limit="0.33" upper_limit="0.57"/>
                    <measurement group_id="O12" value="0.61" lower_limit="0.49" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="42"/>
                    <count group_id="O10" value="48"/>
                    <count group_id="O11" value="46"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="2.16" upper_limit="3.48"/>
                    <measurement group_id="O2" value="1.97" lower_limit="1.41" upper_limit="2.74"/>
                    <measurement group_id="O3" value="2.43" lower_limit="1.85" upper_limit="3.19"/>
                    <measurement group_id="O4" value="2.13" lower_limit="1.64" upper_limit="2.76"/>
                    <measurement group_id="O5" value="2.18" lower_limit="1.69" upper_limit="2.81"/>
                    <measurement group_id="O6" value="1.52" lower_limit="0.98" upper_limit="2.34"/>
                    <measurement group_id="O7" value="2.16" lower_limit="1.47" upper_limit="3.18"/>
                    <measurement group_id="O8" value="2.32" lower_limit="1.6" upper_limit="3.36"/>
                    <measurement group_id="O9" value="2.51" lower_limit="1.96" upper_limit="3.22"/>
                    <measurement group_id="O10" value="1.74" lower_limit="1.23" upper_limit="2.45"/>
                    <measurement group_id="O11" value="1.84" lower_limit="1.36" upper_limit="2.49"/>
                    <measurement group_id="O12" value="2.29" lower_limit="1.79" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="43"/>
                    <count group_id="O12" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.07" upper_limit="1.64"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.75" upper_limit="1.23"/>
                    <measurement group_id="O3" value="0.89" lower_limit="0.74" upper_limit="1.07"/>
                    <measurement group_id="O4" value="1.08" lower_limit="0.8" upper_limit="1.46"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.9" upper_limit="1.35"/>
                    <measurement group_id="O6" value="1.09" lower_limit="0.89" upper_limit="1.34"/>
                    <measurement group_id="O7" value="1.07" lower_limit="0.89" upper_limit="1.29"/>
                    <measurement group_id="O8" value="1.31" lower_limit="1.02" upper_limit="1.67"/>
                    <measurement group_id="O9" value="1.11" lower_limit="0.83" upper_limit="1.49"/>
                    <measurement group_id="O10" value="0.84" lower_limit="0.67" upper_limit="1.06"/>
                    <measurement group_id="O11" value="0.98" lower_limit="0.79" upper_limit="1.22"/>
                    <measurement group_id="O12" value="0.97" lower_limit="0.76" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="4.59" upper_limit="7.21"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.33" upper_limit="5.31"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.24" upper_limit="5.46"/>
                    <measurement group_id="O4" value="4.96" lower_limit="3.77" upper_limit="6.54"/>
                    <measurement group_id="O5" value="4.36" lower_limit="3.35" upper_limit="5.66"/>
                    <measurement group_id="O6" value="3.93" lower_limit="3.04" upper_limit="5.08"/>
                    <measurement group_id="O7" value="5.43" lower_limit="4.13" upper_limit="7.14"/>
                    <measurement group_id="O8" value="5.55" lower_limit="4.38" upper_limit="7.04"/>
                    <measurement group_id="O9" value="4.93" lower_limit="3.64" upper_limit="6.69"/>
                    <measurement group_id="O10" value="3.89" lower_limit="2.98" upper_limit="5.1"/>
                    <measurement group_id="O11" value="4.63" lower_limit="3.56" upper_limit="6.04"/>
                    <measurement group_id="O12" value="4.52" lower_limit="3.31" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="50"/>
                    <count group_id="O11" value="47"/>
                    <count group_id="O12" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.82" upper_limit="1.39"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.67" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.67" upper_limit="1.03"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.79" upper_limit="1.36"/>
                    <measurement group_id="O5" value="1.03" lower_limit="0.81" upper_limit="1.3"/>
                    <measurement group_id="O6" value="0.93" lower_limit="0.76" upper_limit="1.14"/>
                    <measurement group_id="O7" value="1.09" lower_limit="0.83" upper_limit="1.44"/>
                    <measurement group_id="O8" value="0.92" lower_limit="0.76" upper_limit="1.12"/>
                    <measurement group_id="O9" value="1.09" lower_limit="0.82" upper_limit="1.46"/>
                    <measurement group_id="O10" value="0.74" lower_limit="0.58" upper_limit="0.95"/>
                    <measurement group_id="O11" value="0.93" lower_limit="0.76" upper_limit="1.14"/>
                    <measurement group_id="O12" value="0.97" lower_limit="0.73" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="42"/>
                    <count group_id="O10" value="48"/>
                    <count group_id="O11" value="46"/>
                    <count group_id="O12" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" lower_limit="3.35" upper_limit="5.93"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.47" upper_limit="4.41"/>
                    <measurement group_id="O3" value="3.94" lower_limit="2.8" upper_limit="5.54"/>
                    <measurement group_id="O4" value="3.47" lower_limit="2.76" upper_limit="4.36"/>
                    <measurement group_id="O5" value="3.16" lower_limit="2.39" upper_limit="4.17"/>
                    <measurement group_id="O6" value="3.07" lower_limit="2.32" upper_limit="4.07"/>
                    <measurement group_id="O7" value="4.07" lower_limit="3" upper_limit="5.52"/>
                    <measurement group_id="O8" value="3.88" lower_limit="3.09" upper_limit="4.87"/>
                    <measurement group_id="O9" value="4.05" lower_limit="3.18" upper_limit="5.15"/>
                    <measurement group_id="O10" value="3.11" lower_limit="2.36" upper_limit="4.09"/>
                    <measurement group_id="O11" value="3.49" lower_limit="2.68" upper_limit="4.56"/>
                    <measurement group_id="O12" value="3.9" lower_limit="2.86" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.23" upper_limit="2.51"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.25" upper_limit="2.41"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.71" upper_limit="1.57"/>
                    <measurement group_id="O4" value="1.31" lower_limit="0.99" upper_limit="1.74"/>
                    <measurement group_id="O5" value="1.7" lower_limit="1.18" upper_limit="2.44"/>
                    <measurement group_id="O6" value="1.73" lower_limit="1.29" upper_limit="2.33"/>
                    <measurement group_id="O7" value="1.6" lower_limit="1.06" upper_limit="2.39"/>
                    <measurement group_id="O8" value="1.93" lower_limit="1.47" upper_limit="2.53"/>
                    <measurement group_id="O9" value="1.95" lower_limit="1.28" upper_limit="2.95"/>
                    <measurement group_id="O10" value="1.18" lower_limit="0.85" upper_limit="1.64"/>
                    <measurement group_id="O11" value="1.53" lower_limit="1.08" upper_limit="2.16"/>
                    <measurement group_id="O12" value="1.86" lower_limit="1.38" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="43"/>
                    <count group_id="O10" value="50"/>
                    <count group_id="O11" value="47"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" lower_limit="4.47" upper_limit="8.12"/>
                    <measurement group_id="O2" value="5.62" lower_limit="3.99" upper_limit="7.92"/>
                    <measurement group_id="O3" value="5.16" lower_limit="3.61" upper_limit="7.36"/>
                    <measurement group_id="O4" value="4.54" lower_limit="3.45" upper_limit="5.98"/>
                    <measurement group_id="O5" value="5.08" lower_limit="3.8" upper_limit="6.8"/>
                    <measurement group_id="O6" value="4.61" lower_limit="3.37" upper_limit="6.3"/>
                    <measurement group_id="O7" value="6.03" lower_limit="4.18" upper_limit="8.7"/>
                    <measurement group_id="O8" value="6.56" lower_limit="5.06" upper_limit="8.51"/>
                    <measurement group_id="O9" value="6.3" lower_limit="4.45" upper_limit="8.92"/>
                    <measurement group_id="O10" value="4.72" lower_limit="3.56" upper_limit="6.27"/>
                    <measurement group_id="O11" value="5.52" lower_limit="4.13" upper_limit="7.38"/>
                    <measurement group_id="O12" value="5.62" lower_limit="4.23" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="46"/>
                    <count group_id="O10" value="50"/>
                    <count group_id="O11" value="47"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.88" upper_limit="1.47"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.81" upper_limit="1.32"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.73" upper_limit="1.26"/>
                    <measurement group_id="O4" value="1.08" lower_limit="0.82" upper_limit="1.41"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.86" upper_limit="1.39"/>
                    <measurement group_id="O6" value="1.03" lower_limit="0.8" upper_limit="1.31"/>
                    <measurement group_id="O7" value="1.12" lower_limit="0.87" upper_limit="1.43"/>
                    <measurement group_id="O8" value="1.39" lower_limit="1.08" upper_limit="1.79"/>
                    <measurement group_id="O9" value="1.23" lower_limit="0.93" upper_limit="1.63"/>
                    <measurement group_id="O10" value="0.91" lower_limit="0.67" upper_limit="1.23"/>
                    <measurement group_id="O11" value="1.14" lower_limit="0.92" upper_limit="1.41"/>
                    <measurement group_id="O12" value="1.31" lower_limit="1.01" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="42"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" lower_limit="7.13" upper_limit="12.25"/>
                    <measurement group_id="O2" value="8.06" lower_limit="5.93" upper_limit="10.96"/>
                    <measurement group_id="O3" value="7.78" lower_limit="5.53" upper_limit="10.93"/>
                    <measurement group_id="O4" value="8.23" lower_limit="6.37" upper_limit="10.65"/>
                    <measurement group_id="O5" value="7.16" lower_limit="5.41" upper_limit="9.46"/>
                    <measurement group_id="O6" value="7.1" lower_limit="5.33" upper_limit="9.46"/>
                    <measurement group_id="O7" value="7.15" lower_limit="5.13" upper_limit="9.96"/>
                    <measurement group_id="O8" value="11.29" lower_limit="7.96" upper_limit="16"/>
                    <measurement group_id="O9" value="8.68" lower_limit="6.41" upper_limit="11.75"/>
                    <measurement group_id="O10" value="6.18" lower_limit="4.65" upper_limit="8.2"/>
                    <measurement group_id="O11" value="8.66" lower_limit="6.76" upper_limit="11.09"/>
                    <measurement group_id="O12" value="8.17" lower_limit="5.8" upper_limit="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="44"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="48"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.46" upper_limit="2.57"/>
                    <measurement group_id="O2" value="1.66" lower_limit="1.28" upper_limit="2.17"/>
                    <measurement group_id="O3" value="1.72" lower_limit="1.23" upper_limit="2.39"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.14" upper_limit="2.19"/>
                    <measurement group_id="O5" value="1.54" lower_limit="1.09" upper_limit="2.19"/>
                    <measurement group_id="O6" value="1.38" lower_limit="1.09" upper_limit="1.75"/>
                    <measurement group_id="O7" value="1.25" lower_limit="0.96" upper_limit="1.63"/>
                    <measurement group_id="O8" value="1.7" lower_limit="1.27" upper_limit="2.26"/>
                    <measurement group_id="O9" value="1.9" lower_limit="1.38" upper_limit="2.62"/>
                    <measurement group_id="O10" value="1.56" lower_limit="1.14" upper_limit="2.13"/>
                    <measurement group_id="O11" value="1.51" lower_limit="1.15" upper_limit="2"/>
                    <measurement group_id="O12" value="1.72" lower_limit="1.31" upper_limit="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.89" upper_limit="9.72"/>
                    <measurement group_id="O2" value="6.64" lower_limit="5.17" upper_limit="8.54"/>
                    <measurement group_id="O3" value="6.91" lower_limit="4.88" upper_limit="9.77"/>
                    <measurement group_id="O4" value="5.35" lower_limit="3.84" upper_limit="7.47"/>
                    <measurement group_id="O5" value="5.27" lower_limit="3.64" upper_limit="7.64"/>
                    <measurement group_id="O6" value="5.57" lower_limit="4.14" upper_limit="7.51"/>
                    <measurement group_id="O7" value="5.24" lower_limit="3.66" upper_limit="7.49"/>
                    <measurement group_id="O8" value="7.26" lower_limit="5.28" upper_limit="9.97"/>
                    <measurement group_id="O9" value="7.34" lower_limit="5.55" upper_limit="9.73"/>
                    <measurement group_id="O10" value="5.94" lower_limit="4.43" upper_limit="7.97"/>
                    <measurement group_id="O11" value="5.54" lower_limit="3.88" upper_limit="7.93"/>
                    <measurement group_id="O12" value="6.66" lower_limit="4.92" upper_limit="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.45" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.52" upper_limit="0.79"/>
                    <measurement group_id="O3" value="0.41" lower_limit="0.28" upper_limit="0.58"/>
                    <measurement group_id="O4" value="0.55" lower_limit="0.39" upper_limit="0.77"/>
                    <measurement group_id="O5" value="0.5" lower_limit="0.34" upper_limit="0.72"/>
                    <measurement group_id="O6" value="0.65" lower_limit="0.5" upper_limit="0.84"/>
                    <measurement group_id="O7" value="0.61" lower_limit="0.45" upper_limit="0.81"/>
                    <measurement group_id="O8" value="0.69" lower_limit="0.51" upper_limit="0.92"/>
                    <measurement group_id="O9" value="0.58" lower_limit="0.43" upper_limit="0.79"/>
                    <measurement group_id="O10" value="0.47" lower_limit="0.34" upper_limit="0.65"/>
                    <measurement group_id="O11" value="0.43" lower_limit="0.3" upper_limit="0.62"/>
                    <measurement group_id="O12" value="0.52" lower_limit="0.37" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" lower_limit="2.6" upper_limit="5.33"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.25" upper_limit="4.21"/>
                    <measurement group_id="O3" value="2.59" lower_limit="1.63" upper_limit="4.11"/>
                    <measurement group_id="O4" value="2.93" lower_limit="2.05" upper_limit="4.19"/>
                    <measurement group_id="O5" value="2.16" lower_limit="1.4" upper_limit="3.33"/>
                    <measurement group_id="O6" value="2.74" lower_limit="2.06" upper_limit="3.65"/>
                    <measurement group_id="O7" value="3.12" lower_limit="2.17" upper_limit="4.48"/>
                    <measurement group_id="O8" value="3.17" lower_limit="2.34" upper_limit="4.31"/>
                    <measurement group_id="O9" value="3.33" lower_limit="2.36" upper_limit="4.7"/>
                    <measurement group_id="O10" value="2.5" lower_limit="1.76" upper_limit="3.56"/>
                    <measurement group_id="O11" value="2.53" lower_limit="1.74" upper_limit="3.68"/>
                    <measurement group_id="O12" value="3.15" lower_limit="2.31" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="48"/>
                    <count group_id="O11" value="45"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.21" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.12" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.17" upper_limit="0.37"/>
                    <measurement group_id="O4" value="0.26" lower_limit="0.18" upper_limit="0.39"/>
                    <measurement group_id="O5" value="0.32" lower_limit="0.23" upper_limit="0.43"/>
                    <measurement group_id="O6" value="0.32" lower_limit="0.21" upper_limit="0.49"/>
                    <measurement group_id="O7" value="0.26" lower_limit="0.17" upper_limit="0.4"/>
                    <measurement group_id="O8" value="0.28" lower_limit="0.19" upper_limit="0.43"/>
                    <measurement group_id="O9" value="0.34" lower_limit="0.24" upper_limit="0.49"/>
                    <measurement group_id="O10" value="0.19" lower_limit="0.13" upper_limit="0.27"/>
                    <measurement group_id="O11" value="0.22" lower_limit="0.16" upper_limit="0.31"/>
                    <measurement group_id="O12" value="0.24" lower_limit="0.17" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="47"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="0.93" upper_limit="1.97"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.56" upper_limit="1.34"/>
                    <measurement group_id="O3" value="1.14" lower_limit="0.72" upper_limit="1.79"/>
                    <measurement group_id="O4" value="0.89" lower_limit="0.57" upper_limit="1.39"/>
                    <measurement group_id="O5" value="1.09" lower_limit="0.78" upper_limit="1.54"/>
                    <measurement group_id="O6" value="0.74" lower_limit="0.49" upper_limit="1.12"/>
                    <measurement group_id="O7" value="1.03" lower_limit="0.61" upper_limit="1.74"/>
                    <measurement group_id="O8" value="0.99" lower_limit="0.66" upper_limit="1.48"/>
                    <measurement group_id="O9" value="1.4" lower_limit="0.97" upper_limit="2.01"/>
                    <measurement group_id="O10" value="0.81" lower_limit="0.53" upper_limit="1.23"/>
                    <measurement group_id="O11" value="0.87" lower_limit="0.59" upper_limit="1.29"/>
                    <measurement group_id="O12" value="0.98" lower_limit="0.67" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="48"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.19" upper_limit="0.42"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.16" upper_limit="0.32"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.15" upper_limit="0.32"/>
                    <measurement group_id="O4" value="0.24" lower_limit="0.16" upper_limit="0.36"/>
                    <measurement group_id="O5" value="0.2" lower_limit="0.14" upper_limit="0.3"/>
                    <measurement group_id="O6" value="0.24" lower_limit="0.17" upper_limit="0.33"/>
                    <measurement group_id="O7" value="0.15" lower_limit="0.11" upper_limit="0.2"/>
                    <measurement group_id="O8" value="0.2" lower_limit="0.14" upper_limit="0.3"/>
                    <measurement group_id="O9" value="0.28" lower_limit="0.19" upper_limit="0.4"/>
                    <measurement group_id="O10" value="0.21" lower_limit="0.15" upper_limit="0.3"/>
                    <measurement group_id="O11" value="0.19" lower_limit="0.13" upper_limit="0.28"/>
                    <measurement group_id="O12" value="0.24" lower_limit="0.16" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.67" upper_limit="1.83"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.78" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.66" upper_limit="1.69"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.48" upper_limit="1.15"/>
                    <measurement group_id="O5" value="0.66" lower_limit="0.4" upper_limit="1.1"/>
                    <measurement group_id="O6" value="0.95" lower_limit="0.61" upper_limit="1.48"/>
                    <measurement group_id="O7" value="0.67" lower_limit="0.43" upper_limit="1.04"/>
                    <measurement group_id="O8" value="0.93" lower_limit="0.58" upper_limit="1.47"/>
                    <measurement group_id="O9" value="0.97" lower_limit="0.61" upper_limit="1.53"/>
                    <measurement group_id="O10" value="0.74" lower_limit="0.49" upper_limit="1.1"/>
                    <measurement group_id="O11" value="0.63" lower_limit="0.37" upper_limit="1.09"/>
                    <measurement group_id="O12" value="1.11" lower_limit="0.71" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes</title>
        <description>OPA titers against pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was an antibody titer ≥ 8.</description>
        <time_frame>One month after primary immunization (Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results or antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes</title>
          <description>OPA titers against pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was an antibody titer ≥ 8.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results or antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="26.5" upper_limit="182"/>
                    <measurement group_id="O2" value="67.9" lower_limit="28.9" upper_limit="159.6"/>
                    <measurement group_id="O3" value="75.9" lower_limit="32.5" upper_limit="177"/>
                    <measurement group_id="O4" value="23" lower_limit="6.1" upper_limit="86.8"/>
                    <measurement group_id="O5" value="94" lower_limit="31.8" upper_limit="277.8"/>
                    <measurement group_id="O6" value="64.4" lower_limit="12.9" upper_limit="320.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1311" lower_limit="848.8" upper_limit="2024.8"/>
                    <measurement group_id="O2" value="1172.3" lower_limit="639.7" upper_limit="2148.3"/>
                    <measurement group_id="O3" value="1027.7" lower_limit="573" upper_limit="1843.1"/>
                    <measurement group_id="O4" value="684.8" lower_limit="211.7" upper_limit="2215.5"/>
                    <measurement group_id="O5" value="1712.4" lower_limit="857" upper_limit="3421.6"/>
                    <measurement group_id="O6" value="777.2" lower_limit="119.2" upper_limit="5068.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="45" upper_limit="167"/>
                    <measurement group_id="O2" value="52.4" lower_limit="28.2" upper_limit="97.6"/>
                    <measurement group_id="O3" value="74.3" lower_limit="40.6" upper_limit="136.1"/>
                    <measurement group_id="O4" value="38.7" lower_limit="14.5" upper_limit="103"/>
                    <measurement group_id="O5" value="70.7" lower_limit="29.8" upper_limit="167.7"/>
                    <measurement group_id="O6" value="80.8" lower_limit="16.5" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="723" lower_limit="434.8" upper_limit="1202.3"/>
                    <measurement group_id="O2" value="882.4" lower_limit="331.1" upper_limit="2351.7"/>
                    <measurement group_id="O3" value="361.3" lower_limit="125.7" upper_limit="1038.4"/>
                    <measurement group_id="O4" value="739.9" lower_limit="346.5" upper_limit="1580"/>
                    <measurement group_id="O5" value="140.3" lower_limit="27.6" upper_limit="712.2"/>
                    <measurement group_id="O6" value="237.1" lower_limit="30.5" upper_limit="1839.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8827.7" lower_limit="5905.7" upper_limit="13195.4"/>
                    <measurement group_id="O2" value="4977.9" lower_limit="3312.3" upper_limit="7481.1"/>
                    <measurement group_id="O3" value="6444.8" lower_limit="3781" upper_limit="10985.5"/>
                    <measurement group_id="O4" value="8362.7" lower_limit="4221.1" upper_limit="16567.7"/>
                    <measurement group_id="O5" value="7306.4" lower_limit="4248.7" upper_limit="12564.7"/>
                    <measurement group_id="O6" value="6286.1" lower_limit="3990.3" upper_limit="9902.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3429.2" lower_limit="2184.2" upper_limit="5384"/>
                    <measurement group_id="O2" value="4040.4" lower_limit="1816.6" upper_limit="8986.3"/>
                    <measurement group_id="O3" value="2744.2" lower_limit="1307.7" upper_limit="5758.7"/>
                    <measurement group_id="O4" value="5520.1" lower_limit="2214.2" upper_limit="13762"/>
                    <measurement group_id="O5" value="3777.1" lower_limit="1309.9" upper_limit="10891.1"/>
                    <measurement group_id="O6" value="2273.2" lower_limit="1339.4" upper_limit="3858.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1346.3" lower_limit="522.8" upper_limit="3467"/>
                    <measurement group_id="O2" value="1219.7" lower_limit="551.1" upper_limit="2699.6"/>
                    <measurement group_id="O3" value="1417.9" lower_limit="940.6" upper_limit="2137.3"/>
                    <measurement group_id="O4" value="591.5" lower_limit="121.6" upper_limit="2877.4"/>
                    <measurement group_id="O5" value="1780.5" lower_limit="811.9" upper_limit="3905"/>
                    <measurement group_id="O6" value="1460.1" lower_limit="777.2" upper_limit="2742.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.9" lower_limit="129.5" upper_limit="269.8"/>
                    <measurement group_id="O2" value="167.6" lower_limit="67.4" upper_limit="417.2"/>
                    <measurement group_id="O3" value="135.9" lower_limit="51.4" upper_limit="359.5"/>
                    <measurement group_id="O4" value="91.6" lower_limit="13.7" upper_limit="611.6"/>
                    <measurement group_id="O5" value="382.7" lower_limit="136" upper_limit="1076.8"/>
                    <measurement group_id="O6" value="106" lower_limit="22.2" upper_limit="507.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536.2" lower_limit="361.9" upper_limit="794.5"/>
                    <measurement group_id="O2" value="514.8" lower_limit="346.7" upper_limit="764.3"/>
                    <measurement group_id="O3" value="267.9" lower_limit="110.4" upper_limit="650.3"/>
                    <measurement group_id="O4" value="501.1" lower_limit="247.4" upper_limit="1015.3"/>
                    <measurement group_id="O5" value="254.2" lower_limit="59.1" upper_limit="1093.9"/>
                    <measurement group_id="O6" value="272.1" lower_limit="45" upper_limit="1646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="989.8" lower_limit="298.1" upper_limit="3286.3"/>
                    <measurement group_id="O2" value="1105.5" lower_limit="323.9" upper_limit="3772.4"/>
                    <measurement group_id="O3" value="1296" lower_limit="473.4" upper_limit="3548.1"/>
                    <measurement group_id="O4" value="1188.4" lower_limit="206" upper_limit="6855.2"/>
                    <measurement group_id="O5" value="723" lower_limit="137.3" upper_limit="3805.9"/>
                    <measurement group_id="O6" value="838.4" lower_limit="111.4" upper_limit="6313.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="25.5" upper_limit="245.4"/>
                    <measurement group_id="O2" value="151.1" lower_limit="27.2" upper_limit="838.2"/>
                    <measurement group_id="O3" value="26.4" lower_limit="9" upper_limit="77"/>
                    <measurement group_id="O4" value="100.7" lower_limit="21.7" upper_limit="466.4"/>
                    <measurement group_id="O5" value="34.2" lower_limit="6.4" upper_limit="184.1"/>
                    <measurement group_id="O6" value="44.5" lower_limit="4.8" upper_limit="411.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="4.8" upper_limit="57.6"/>
                    <measurement group_id="O2" value="46.1" lower_limit="13.4" upper_limit="158.2"/>
                    <measurement group_id="O3" value="20.4" lower_limit="5.3" upper_limit="79.2"/>
                    <measurement group_id="O4" value="11.2" lower_limit="2.1" upper_limit="59.9"/>
                    <measurement group_id="O5" value="39.7" lower_limit="9.9" upper_limit="158.5"/>
                    <measurement group_id="O6" value="11.4" lower_limit="0.4" upper_limit="315.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes</title>
        <description>OPA titers against pneumococcal serotypes (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was ≥ 8. When the number of subjects in a group for a specific category equals (=) 1, the lower limit and upper limit of the confidence interval that can't be calculated, are filled in with the GMT value (due to system constraint). Placeholder value &quot;99999.9&quot; has been entered when value to be entered in the system was greater than (&gt;) 1.0 E10.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes</title>
          <description>OPA titers against pneumococcal serotypes (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was ≥ 8. When the number of subjects in a group for a specific category equals (=) 1, the lower limit and upper limit of the confidence interval that can't be calculated, are filled in with the GMT value (due to system constraint). Placeholder value &quot;99999.9&quot; has been entered when value to be entered in the system was greater than (&gt;) 1.0 E10.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="11"/>
                <count group_id="O12" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="10"/>
                    <count group_id="O12" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="2.2" upper_limit="15.3"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="50.3" lower_limit="0.1" upper_limit="18959.2"/>
                    <measurement group_id="O5" value="50.6" lower_limit="10.3" upper_limit="248.5"/>
                    <measurement group_id="O6" value="9.9" lower_limit="2.2" upper_limit="44.5"/>
                    <measurement group_id="O7" value="7.3" lower_limit="1.7" upper_limit="31.9"/>
                    <measurement group_id="O8" value="40.2" lower_limit="2.5" upper_limit="638.5"/>
                    <measurement group_id="O9" value="10.7" lower_limit="0.5" upper_limit="242.8"/>
                    <measurement group_id="O10" value="6" lower_limit="2.4" upper_limit="15"/>
                    <measurement group_id="O11" value="12.2" lower_limit="4.3" upper_limit="34.1"/>
                    <measurement group_id="O12" value="15.7" lower_limit="4.4" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346.2" lower_limit="96.8" upper_limit="1237.9"/>
                    <measurement group_id="O2" value="296.3" lower_limit="31" upper_limit="2828.6"/>
                    <measurement group_id="O3" value="316.4" lower_limit="96.8" upper_limit="1034.8"/>
                    <measurement group_id="O4" value="158" lower_limit="10.2" upper_limit="2438.7"/>
                    <measurement group_id="O5" value="248" lower_limit="67.5" upper_limit="911.1"/>
                    <measurement group_id="O6" value="344.4" lower_limit="105.7" upper_limit="1122.1"/>
                    <measurement group_id="O7" value="388.2" lower_limit="134.4" upper_limit="1121.8"/>
                    <measurement group_id="O8" value="546.2" lower_limit="75.4" upper_limit="3956.8"/>
                    <measurement group_id="O9" value="627" lower_limit="37" upper_limit="10621.6"/>
                    <measurement group_id="O10" value="120.6" lower_limit="10.8" upper_limit="1346.5"/>
                    <measurement group_id="O11" value="736.3" lower_limit="184.7" upper_limit="2934.6"/>
                    <measurement group_id="O12" value="887.6" lower_limit="226.3" upper_limit="3481.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="0.7" upper_limit="1751.4"/>
                    <measurement group_id="O2" value="80.2" lower_limit="3.1" upper_limit="2046.3"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="9" lower_limit="9" upper_limit="9"/>
                    <measurement group_id="O5" value="407.6" lower_limit="178.5" upper_limit="930.7"/>
                    <measurement group_id="O6" value="74.2" lower_limit="10.1" upper_limit="546.3"/>
                    <measurement group_id="O7" value="98.1" lower_limit="13.7" upper_limit="703"/>
                    <measurement group_id="O8" value="52.4" lower_limit="4" upper_limit="681.7"/>
                    <measurement group_id="O9" value="15.2" lower_limit="2.9" upper_limit="80.3"/>
                    <measurement group_id="O10" value="25.9" lower_limit="3" upper_limit="227"/>
                    <measurement group_id="O11" value="56.3" lower_limit="7.2" upper_limit="442"/>
                    <measurement group_id="O12" value="161.8" lower_limit="14.5" upper_limit="1807.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="928.1" lower_limit="309.6" upper_limit="2781.8"/>
                    <measurement group_id="O2" value="865.8" lower_limit="48.5" upper_limit="15451.2"/>
                    <measurement group_id="O3" value="2213.4" lower_limit="438.4" upper_limit="11174.3"/>
                    <measurement group_id="O4" value="2096.7" lower_limit="828.7" upper_limit="5304.9"/>
                    <measurement group_id="O5" value="1037.5" lower_limit="310.2" upper_limit="3469.2"/>
                    <measurement group_id="O6" value="1096.7" lower_limit="266.3" upper_limit="4516.1"/>
                    <measurement group_id="O7" value="1953.4" lower_limit="972.9" upper_limit="3922.2"/>
                    <measurement group_id="O8" value="1149.8" lower_limit="209.9" upper_limit="6297.3"/>
                    <measurement group_id="O9" value="1414.1" lower_limit="738.6" upper_limit="2707.3"/>
                    <measurement group_id="O10" value="548.3" lower_limit="15" upper_limit="20011.5"/>
                    <measurement group_id="O11" value="1885.9" lower_limit="1047.9" upper_limit="3394"/>
                    <measurement group_id="O12" value="854.4" lower_limit="51.9" upper_limit="14066.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="4.6" upper_limit="36.3"/>
                    <measurement group_id="O2" value="9.2" lower_limit="3.2" upper_limit="26.5"/>
                    <measurement group_id="O3" value="8.2" lower_limit="0.4" upper_limit="185"/>
                    <measurement group_id="O4" value="19" lower_limit="0.5" upper_limit="699.8"/>
                    <measurement group_id="O5" value="17.5" lower_limit="4" upper_limit="76"/>
                    <measurement group_id="O6" value="10.8" lower_limit="2.8" upper_limit="41.7"/>
                    <measurement group_id="O7" value="7.6" lower_limit="2.6" upper_limit="21.8"/>
                    <measurement group_id="O8" value="12.7" lower_limit="1.4" upper_limit="114.2"/>
                    <measurement group_id="O9" value="9.8" lower_limit="3.7" upper_limit="26"/>
                    <measurement group_id="O10" value="5.7" lower_limit="3.3" upper_limit="10.1"/>
                    <measurement group_id="O11" value="7.4" lower_limit="4.5" upper_limit="12.3"/>
                    <measurement group_id="O12" value="22.2" lower_limit="6.4" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" lower_limit="77.7" upper_limit="223.6"/>
                    <measurement group_id="O2" value="93.3" lower_limit="15.5" upper_limit="562.2"/>
                    <measurement group_id="O3" value="241.7" lower_limit="19.1" upper_limit="3061.6"/>
                    <measurement group_id="O4" value="79" lower_limit="7.6" upper_limit="826.1"/>
                    <measurement group_id="O5" value="114.1" lower_limit="17.2" upper_limit="758.5"/>
                    <measurement group_id="O6" value="165.8" lower_limit="75.4" upper_limit="364.8"/>
                    <measurement group_id="O7" value="99.5" lower_limit="36.2" upper_limit="273.8"/>
                    <measurement group_id="O8" value="128.9" lower_limit="16.8" upper_limit="989.4"/>
                    <measurement group_id="O9" value="184.6" lower_limit="20.4" upper_limit="1671.3"/>
                    <measurement group_id="O10" value="42.2" lower_limit="6.3" upper_limit="283"/>
                    <measurement group_id="O11" value="125.3" lower_limit="43.6" upper_limit="360.3"/>
                    <measurement group_id="O12" value="149.7" lower_limit="27.8" upper_limit="806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="0.1" upper_limit="90019.7"/>
                    <measurement group_id="O2" value="237.2" lower_limit="86.5" upper_limit="650.7"/>
                    <measurement group_id="O3" value="84.3" lower_limit="0.1" upper_limit="63745.1"/>
                    <measurement group_id="O4" value="13.3" lower_limit="0" upper_limit="54806323"/>
                    <measurement group_id="O5" value="289.4" lower_limit="9.8" upper_limit="8513.4"/>
                    <measurement group_id="O6" value="208.9" lower_limit="12.9" upper_limit="3385.1"/>
                    <measurement group_id="O7" value="16.4" lower_limit="1.2" upper_limit="229.5"/>
                    <measurement group_id="O8" value="13.7" lower_limit="0" upper_limit="86126942"/>
                    <measurement group_id="O9" value="182.5" lower_limit="18.9" upper_limit="1765.4"/>
                    <measurement group_id="O10" value="127.7" lower_limit="6.1" upper_limit="2672.4"/>
                    <measurement group_id="O11" value="105.6" lower_limit="22.7" upper_limit="492.5"/>
                    <measurement group_id="O12" value="239" lower_limit="239" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745.6" lower_limit="129.8" upper_limit="4282.1"/>
                    <measurement group_id="O2" value="606.2" lower_limit="42" upper_limit="8748.2"/>
                    <measurement group_id="O3" value="769.1" lower_limit="98.3" upper_limit="6016.6"/>
                    <measurement group_id="O4" value="694.2" lower_limit="296.4" upper_limit="1626.1"/>
                    <measurement group_id="O5" value="553.1" lower_limit="61.9" upper_limit="4943.5"/>
                    <measurement group_id="O6" value="1021.6" lower_limit="405.4" upper_limit="2574.3"/>
                    <measurement group_id="O7" value="237.6" lower_limit="50.1" upper_limit="1127.3"/>
                    <measurement group_id="O8" value="173.1" lower_limit="2" upper_limit="14809"/>
                    <measurement group_id="O9" value="1047.8" lower_limit="203.5" upper_limit="5394.1"/>
                    <measurement group_id="O10" value="431.5" lower_limit="26.4" upper_limit="7055.2"/>
                    <measurement group_id="O11" value="904.3" lower_limit="416.8" upper_limit="1961.9"/>
                    <measurement group_id="O12" value="376.5" lower_limit="92.7" upper_limit="1529.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2076" lower_limit="972" upper_limit="4433.7"/>
                    <measurement group_id="O2" value="1777.3" lower_limit="826.6" upper_limit="3821.5"/>
                    <measurement group_id="O3" value="1762.5" lower_limit="499.8" upper_limit="6215"/>
                    <measurement group_id="O4" value="1729.9" lower_limit="44.7" upper_limit="66995.8"/>
                    <measurement group_id="O5" value="5343.2" lower_limit="1372.2" upper_limit="20805"/>
                    <measurement group_id="O6" value="3522.8" lower_limit="1918.3" upper_limit="6469.5"/>
                    <measurement group_id="O7" value="2563" lower_limit="1240.6" upper_limit="5295.2"/>
                    <measurement group_id="O8" value="1152" lower_limit="421.9" upper_limit="3145.6"/>
                    <measurement group_id="O9" value="1263.5" lower_limit="941.3" upper_limit="1696"/>
                    <measurement group_id="O10" value="1290.9" lower_limit="705" upper_limit="2363.9"/>
                    <measurement group_id="O11" value="2256.2" lower_limit="1405.5" upper_limit="3622"/>
                    <measurement group_id="O12" value="1744.7" lower_limit="1196.4" upper_limit="2544.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16259.9" lower_limit="3902.8" upper_limit="67742.7"/>
                    <measurement group_id="O2" value="4591.4" lower_limit="1411.4" upper_limit="14936.5"/>
                    <measurement group_id="O3" value="12162.6" lower_limit="776.4" upper_limit="190521.8"/>
                    <measurement group_id="O4" value="11741" lower_limit="6560.1" upper_limit="21013.7"/>
                    <measurement group_id="O5" value="9941.8" lower_limit="8127.1" upper_limit="12161.8"/>
                    <measurement group_id="O6" value="5744.5" lower_limit="1641" upper_limit="20109.7"/>
                    <measurement group_id="O7" value="14362.4" lower_limit="7145.2" upper_limit="28869.5"/>
                    <measurement group_id="O8" value="3565.8" lower_limit="921.7" upper_limit="13795.9"/>
                    <measurement group_id="O9" value="5829.1" lower_limit="2843" upper_limit="11951.8"/>
                    <measurement group_id="O10" value="11414.1" lower_limit="394.1" upper_limit="330587.3"/>
                    <measurement group_id="O11" value="21670" lower_limit="6757.9" upper_limit="69487.8"/>
                    <measurement group_id="O12" value="7567.3" lower_limit="2674.9" upper_limit="21408.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830" lower_limit="289.3" upper_limit="2381"/>
                    <measurement group_id="O2" value="1283.8" lower_limit="523.1" upper_limit="3150.9"/>
                    <measurement group_id="O3" value="649.4" lower_limit="55.7" upper_limit="7568.6"/>
                    <measurement group_id="O4" value="1302.7" lower_limit="463.1" upper_limit="3664.3"/>
                    <measurement group_id="O5" value="1423.6" lower_limit="322.4" upper_limit="6284.8"/>
                    <measurement group_id="O6" value="1081.9" lower_limit="332.8" upper_limit="3517.5"/>
                    <measurement group_id="O7" value="1075.2" lower_limit="296.2" upper_limit="3903.4"/>
                    <measurement group_id="O8" value="282.1" lower_limit="31.3" upper_limit="2546.4"/>
                    <measurement group_id="O9" value="1571.3" lower_limit="115.1" upper_limit="21457.3"/>
                    <measurement group_id="O10" value="567.4" lower_limit="200.7" upper_limit="1604.5"/>
                    <measurement group_id="O11" value="480.9" lower_limit="277.4" upper_limit="833.4"/>
                    <measurement group_id="O12" value="738.7" lower_limit="380.4" upper_limit="1434.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4969" lower_limit="1397.5" upper_limit="17668"/>
                    <measurement group_id="O2" value="7041.7" lower_limit="275.3" upper_limit="180111.2"/>
                    <measurement group_id="O3" value="4756.1" lower_limit="1023.5" upper_limit="22100.8"/>
                    <measurement group_id="O4" value="4190.8" lower_limit="2825.5" upper_limit="6215.9"/>
                    <measurement group_id="O5" value="3772.9" lower_limit="80.6" upper_limit="176558.2"/>
                    <measurement group_id="O6" value="4970.9" lower_limit="936.8" upper_limit="26377"/>
                    <measurement group_id="O7" value="4218.9" lower_limit="1894.6" upper_limit="9394.3"/>
                    <measurement group_id="O8" value="2919.8" lower_limit="474" upper_limit="17985"/>
                    <measurement group_id="O9" value="8601.7" lower_limit="382.8" upper_limit="193287.2"/>
                    <measurement group_id="O10" value="856.6" lower_limit="128.2" upper_limit="5724.3"/>
                    <measurement group_id="O11" value="7262.2" lower_limit="2971.8" upper_limit="17746.7"/>
                    <measurement group_id="O12" value="1340.1" lower_limit="362" upper_limit="4961.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.2" lower_limit="9.9" upper_limit="2241.1"/>
                    <measurement group_id="O2" value="255.1" lower_limit="16.7" upper_limit="3888.7"/>
                    <measurement group_id="O3" value="47.2" lower_limit="0" upper_limit="99999.9"/>
                    <measurement group_id="O4" value="737.1" lower_limit="1.4" upper_limit="400658.5"/>
                    <measurement group_id="O5" value="791.7" lower_limit="200.6" upper_limit="3124.5"/>
                    <measurement group_id="O6" value="539.2" lower_limit="251.1" upper_limit="1157.8"/>
                    <measurement group_id="O7" value="295" lower_limit="23.9" upper_limit="3647.4"/>
                    <measurement group_id="O8" value="255.9" lower_limit="99.2" upper_limit="660.2"/>
                    <measurement group_id="O9" value="382.6" lower_limit="115.3" upper_limit="1269.1"/>
                    <measurement group_id="O10" value="98.3" lower_limit="15.8" upper_limit="613"/>
                    <measurement group_id="O11" value="260.7" lower_limit="132.9" upper_limit="511.3"/>
                    <measurement group_id="O12" value="195.4" lower_limit="12.5" upper_limit="3045.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1592.9" lower_limit="687.7" upper_limit="3689.5"/>
                    <measurement group_id="O2" value="671.4" lower_limit="14.8" upper_limit="30474.3"/>
                    <measurement group_id="O3" value="4426.6" lower_limit="692.4" upper_limit="28298.7"/>
                    <measurement group_id="O4" value="1507.6" lower_limit="358" upper_limit="6348.6"/>
                    <measurement group_id="O5" value="2002" lower_limit="134.3" upper_limit="29839.5"/>
                    <measurement group_id="O6" value="1312.4" lower_limit="226.7" upper_limit="7597.8"/>
                    <measurement group_id="O7" value="1498.1" lower_limit="672.9" upper_limit="3335.6"/>
                    <measurement group_id="O8" value="935.3" lower_limit="301.9" upper_limit="2897.7"/>
                    <measurement group_id="O9" value="3817" lower_limit="1256.3" upper_limit="11596.8"/>
                    <measurement group_id="O10" value="557.5" lower_limit="17.8" upper_limit="17418.8"/>
                    <measurement group_id="O11" value="2288" lower_limit="761.1" upper_limit="6878.7"/>
                    <measurement group_id="O12" value="587.5" lower_limit="42.6" upper_limit="8103.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="10"/>
                    <count group_id="O12" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="1.1" upper_limit="45.6"/>
                    <measurement group_id="O2" value="7.2" lower_limit="1.4" upper_limit="35.9"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="11.5" lower_limit="0" upper_limit="7631549"/>
                    <measurement group_id="O5" value="21.9" lower_limit="2.3" upper_limit="205.5"/>
                    <measurement group_id="O6" value="10.9" lower_limit="3.2" upper_limit="37.4"/>
                    <measurement group_id="O7" value="31.9" lower_limit="5.9" upper_limit="174"/>
                    <measurement group_id="O8" value="9.4" lower_limit="3.4" upper_limit="25.9"/>
                    <measurement group_id="O9" value="5.5" lower_limit="2" upper_limit="14.8"/>
                    <measurement group_id="O10" value="6.5" lower_limit="3.1" upper_limit="13.6"/>
                    <measurement group_id="O11" value="19.1" lower_limit="6.5" upper_limit="56.3"/>
                    <measurement group_id="O12" value="14" lower_limit="2.7" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="912.9" lower_limit="365.4" upper_limit="2280.6"/>
                    <measurement group_id="O2" value="207.3" lower_limit="2.1" upper_limit="20168.5"/>
                    <measurement group_id="O3" value="2394.7" lower_limit="2.7" upper_limit="2123879"/>
                    <measurement group_id="O4" value="397.3" lower_limit="71.5" upper_limit="2207.5"/>
                    <measurement group_id="O5" value="650.6" lower_limit="82.6" upper_limit="5122.3"/>
                    <measurement group_id="O6" value="298.1" lower_limit="14.4" upper_limit="6180.8"/>
                    <measurement group_id="O7" value="428.6" lower_limit="155.3" upper_limit="1183.2"/>
                    <measurement group_id="O8" value="707.9" lower_limit="6.7" upper_limit="74589.3"/>
                    <measurement group_id="O9" value="481.3" lower_limit="128.3" upper_limit="1804.6"/>
                    <measurement group_id="O10" value="149.9" lower_limit="2.8" upper_limit="8106"/>
                    <measurement group_id="O11" value="888.9" lower_limit="225.5" upper_limit="3502.9"/>
                    <measurement group_id="O12" value="242.7" lower_limit="24.7" upper_limit="2382.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="10"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="10.7" upper_limit="370.1"/>
                    <measurement group_id="O2" value="32.1" lower_limit="4.2" upper_limit="247.3"/>
                    <measurement group_id="O3" value="88.5" lower_limit="0.7" upper_limit="11624.3"/>
                    <measurement group_id="O4" value="9.7" lower_limit="0.2" upper_limit="438"/>
                    <measurement group_id="O5" value="17.7" lower_limit="1.4" upper_limit="226.2"/>
                    <measurement group_id="O6" value="67.8" lower_limit="19" upper_limit="242.3"/>
                    <measurement group_id="O7" value="15" lower_limit="5.7" upper_limit="39.2"/>
                    <measurement group_id="O8" value="24.2" lower_limit="5.9" upper_limit="98.4"/>
                    <measurement group_id="O9" value="53.2" lower_limit="7.7" upper_limit="365.3"/>
                    <measurement group_id="O10" value="11" lower_limit="5" upper_limit="24.3"/>
                    <measurement group_id="O11" value="42.3" lower_limit="16.4" upper_limit="109.6"/>
                    <measurement group_id="O12" value="48.4" lower_limit="12.9" upper_limit="181.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1112.9" lower_limit="289.7" upper_limit="4274.9"/>
                    <measurement group_id="O2" value="330.5" lower_limit="32.2" upper_limit="3390.7"/>
                    <measurement group_id="O3" value="2575.2" lower_limit="120.5" upper_limit="55029.6"/>
                    <measurement group_id="O4" value="637.1" lower_limit="262.3" upper_limit="1547.9"/>
                    <measurement group_id="O5" value="1040.7" lower_limit="12" upper_limit="90618.7"/>
                    <measurement group_id="O6" value="1575" lower_limit="246.7" upper_limit="10054.3"/>
                    <measurement group_id="O7" value="572.7" lower_limit="332.3" upper_limit="986.9"/>
                    <measurement group_id="O8" value="273.9" lower_limit="0" upper_limit="2588316"/>
                    <measurement group_id="O9" value="250.6" lower_limit="70.4" upper_limit="892.1"/>
                    <measurement group_id="O10" value="163.3" lower_limit="8.6" upper_limit="3091.2"/>
                    <measurement group_id="O11" value="1215.3" lower_limit="222.2" upper_limit="6647.8"/>
                    <measurement group_id="O12" value="511" lower_limit="59.2" upper_limit="4412.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="1" upper_limit="771.2"/>
                    <measurement group_id="O2" value="132.4" lower_limit="2.3" upper_limit="7484.5"/>
                    <measurement group_id="O3" value="22.2" lower_limit="0" upper_limit="35490.8"/>
                    <measurement group_id="O4" value="29.7" lower_limit="0" upper_limit="99999.9"/>
                    <measurement group_id="O5" value="134" lower_limit="2.2" upper_limit="8194.2"/>
                    <measurement group_id="O6" value="396.6" lower_limit="19.4" upper_limit="8113.1"/>
                    <measurement group_id="O7" value="499.7" lower_limit="54.2" upper_limit="4605.6"/>
                    <measurement group_id="O8" value="30.5" lower_limit="0" upper_limit="190610.3"/>
                    <measurement group_id="O9" value="15.6" lower_limit="1.1" upper_limit="212.9"/>
                    <measurement group_id="O10" value="89.4" lower_limit="4.8" upper_limit="1668.6"/>
                    <measurement group_id="O11" value="274.5" lower_limit="30.2" upper_limit="2491.4"/>
                    <measurement group_id="O12" value="37.7" lower_limit="0.8" upper_limit="1716.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581" lower_limit="14.5" upper_limit="23210.4"/>
                    <measurement group_id="O2" value="2381.5" lower_limit="861.8" upper_limit="6581"/>
                    <measurement group_id="O3" value="2792.9" lower_limit="391" upper_limit="19949.8"/>
                    <measurement group_id="O4" value="2977.7" lower_limit="687.2" upper_limit="12903.5"/>
                    <measurement group_id="O5" value="2096.1" lower_limit="823.2" upper_limit="5337.4"/>
                    <measurement group_id="O6" value="3530.1" lower_limit="1606.2" upper_limit="7758.5"/>
                    <measurement group_id="O7" value="4249.1" lower_limit="2398" upper_limit="7529.2"/>
                    <measurement group_id="O8" value="3682.7" lower_limit="1187" upper_limit="11426"/>
                    <measurement group_id="O9" value="1464.1" lower_limit="437.9" upper_limit="4895.2"/>
                    <measurement group_id="O10" value="297" lower_limit="2" upper_limit="44387.7"/>
                    <measurement group_id="O11" value="1436.2" lower_limit="114.1" upper_limit="18085.7"/>
                    <measurement group_id="O12" value="875.2" lower_limit="92.2" upper_limit="8311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="0.6" upper_limit="2715.5"/>
                    <measurement group_id="O2" value="45.1" lower_limit="2.8" upper_limit="721.4"/>
                    <measurement group_id="O3" value="13.4" lower_limit="0.1" upper_limit="2451"/>
                    <measurement group_id="O4" value="239.5" lower_limit="21.3" upper_limit="2696.8"/>
                    <measurement group_id="O5" value="224.8" lower_limit="41.3" upper_limit="1222.9"/>
                    <measurement group_id="O6" value="99" lower_limit="12.8" upper_limit="765.5"/>
                    <measurement group_id="O7" value="23.3" lower_limit="3" upper_limit="180.7"/>
                    <measurement group_id="O8" value="34.1" lower_limit="1.5" upper_limit="760.2"/>
                    <measurement group_id="O9" value="58.3" lower_limit="1.3" upper_limit="2537.6"/>
                    <measurement group_id="O10" value="46.7" lower_limit="5.1" upper_limit="428.4"/>
                    <measurement group_id="O11" value="84" lower_limit="11.2" upper_limit="631.4"/>
                    <measurement group_id="O12" value="24.5" lower_limit="4.1" upper_limit="148.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.7" lower_limit="7.3" upper_limit="4625.8"/>
                    <measurement group_id="O2" value="125.4" lower_limit="14" upper_limit="1123.6"/>
                    <measurement group_id="O3" value="318.4" lower_limit="160.1" upper_limit="632.9"/>
                    <measurement group_id="O4" value="581.1" lower_limit="220.5" upper_limit="1531.4"/>
                    <measurement group_id="O5" value="74.5" lower_limit="0.1" upper_limit="40934.6"/>
                    <measurement group_id="O6" value="169.2" lower_limit="2.9" upper_limit="9717.7"/>
                    <measurement group_id="O7" value="98.1" lower_limit="21" upper_limit="458.5"/>
                    <measurement group_id="O8" value="106.9" lower_limit="6.5" upper_limit="1749.7"/>
                    <measurement group_id="O9" value="120" lower_limit="0.1" upper_limit="185061.8"/>
                    <measurement group_id="O10" value="154" lower_limit="8.4" upper_limit="2814.5"/>
                    <measurement group_id="O11" value="159.1" lower_limit="9.9" upper_limit="2554.8"/>
                    <measurement group_id="O12" value="78.5" lower_limit="10.4" upper_limit="592.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="7"/>
                    <count group_id="O12" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="7.4" lower_limit="1.5" upper_limit="36.3"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O7" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O8" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O9" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O10" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O11" value="9.1" lower_limit="2.5" upper_limit="33.5"/>
                    <measurement group_id="O12" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.7" lower_limit="0" upper_limit="5716540"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="21.2" lower_limit="0" upper_limit="99999.9"/>
                    <measurement group_id="O4" value="28" lower_limit="0.4" upper_limit="1990.5"/>
                    <measurement group_id="O5" value="29.8" lower_limit="0" upper_limit="169123.8"/>
                    <measurement group_id="O6" value="325.4" lower_limit="1.9" upper_limit="56037.4"/>
                    <measurement group_id="O7" value="125.7" lower_limit="25.1" upper_limit="627.8"/>
                    <measurement group_id="O8" value="253" lower_limit="253" upper_limit="253"/>
                    <measurement group_id="O9" value="12.8" lower_limit="0" upper_limit="33779569"/>
                    <measurement group_id="O10" value="44.3" lower_limit="0.2" upper_limit="11784.5"/>
                    <measurement group_id="O11" value="416.5" lower_limit="108.9" upper_limit="1593"/>
                    <measurement group_id="O12" value="541.6" lower_limit="22" upper_limit="13332.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Protein D (Anti-PD)</title>
        <description>Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U//mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 100 EL.U/mL.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Protein D (Anti-PD)</title>
          <description>Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U//mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 100 EL.U/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="50"/>
                <count group_id="O11" value="48"/>
                <count group_id="O12" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="46"/>
                    <count group_id="O10" value="50"/>
                    <count group_id="O11" value="46"/>
                    <count group_id="O12" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661.6" lower_limit="517.8" upper_limit="845.4"/>
                    <measurement group_id="O2" value="660.4" lower_limit="501.1" upper_limit="870.4"/>
                    <measurement group_id="O3" value="588.3" lower_limit="431.8" upper_limit="801.5"/>
                    <measurement group_id="O4" value="622.9" lower_limit="472" upper_limit="821.9"/>
                    <measurement group_id="O5" value="590" lower_limit="456.3" upper_limit="763"/>
                    <measurement group_id="O6" value="502" lower_limit="376.6" upper_limit="669.2"/>
                    <measurement group_id="O7" value="752.1" lower_limit="561.2" upper_limit="1008"/>
                    <measurement group_id="O8" value="555.1" lower_limit="423.1" upper_limit="728.2"/>
                    <measurement group_id="O9" value="777.2" lower_limit="561.4" upper_limit="1076"/>
                    <measurement group_id="O10" value="446.1" lower_limit="331.1" upper_limit="601"/>
                    <measurement group_id="O11" value="525.4" lower_limit="367.8" upper_limit="750.4"/>
                    <measurement group_id="O12" value="691.3" lower_limit="550.1" upper_limit="868.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="47"/>
                    <count group_id="O9" value="43"/>
                    <count group_id="O10" value="50"/>
                    <count group_id="O11" value="48"/>
                    <count group_id="O12" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2069" lower_limit="1639.7" upper_limit="2610.8"/>
                    <measurement group_id="O2" value="1980.1" lower_limit="1484.1" upper_limit="2641.8"/>
                    <measurement group_id="O3" value="1907.5" lower_limit="1330.9" upper_limit="2733.9"/>
                    <measurement group_id="O4" value="1888.7" lower_limit="1349.3" upper_limit="2643.6"/>
                    <measurement group_id="O5" value="1664.8" lower_limit="1283" upper_limit="2160.2"/>
                    <measurement group_id="O6" value="1540.7" lower_limit="1108.6" upper_limit="2141.2"/>
                    <measurement group_id="O7" value="2319.7" lower_limit="1701.9" upper_limit="3161.8"/>
                    <measurement group_id="O8" value="1953.1" lower_limit="1541.5" upper_limit="2474.5"/>
                    <measurement group_id="O9" value="2285.5" lower_limit="1724.1" upper_limit="3029.7"/>
                    <measurement group_id="O10" value="1482.7" lower_limit="1077.1" upper_limit="2040.9"/>
                    <measurement group_id="O11" value="1517.3" lower_limit="1134.5" upper_limit="2029.2"/>
                    <measurement group_id="O12" value="2082.5" lower_limit="1634.9" upper_limit="2652.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Diphtheria (D) and Tetanus (T) Toxoids</title>
        <description>Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL.</description>
        <time_frame>One month after primary immunization (Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Diphtheria (D) and Tetanus (T) Toxoids</title>
          <description>Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="153"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.326" lower_limit="2.97" upper_limit="3.725"/>
                    <measurement group_id="O2" value="2.938" lower_limit="2.651" upper_limit="3.257"/>
                    <measurement group_id="O3" value="3.132" lower_limit="2.801" upper_limit="3.503"/>
                    <measurement group_id="O4" value="3.062" lower_limit="2.565" upper_limit="3.655"/>
                    <measurement group_id="O5" value="2.891" lower_limit="2.324" upper_limit="3.597"/>
                    <measurement group_id="O6" value="3.457" lower_limit="2.907" upper_limit="4.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="153"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.746" lower_limit="3.305" upper_limit="4.245"/>
                    <measurement group_id="O2" value="3.373" lower_limit="3.043" upper_limit="3.738"/>
                    <measurement group_id="O3" value="3.961" lower_limit="3.516" upper_limit="4.461"/>
                    <measurement group_id="O4" value="2.943" lower_limit="2.434" upper_limit="3.559"/>
                    <measurement group_id="O5" value="3.058" lower_limit="2.545" upper_limit="3.676"/>
                    <measurement group_id="O6" value="3.762" lower_limit="3.105" upper_limit="4.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Diphteria (D) and Tetanus (T) Toxoids</title>
        <description>Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in IU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Diphteria (D) and Tetanus (T) Toxoids</title>
          <description>Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in IU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="43"/>
                <count group_id="O10" value="47"/>
                <count group_id="O11" value="44"/>
                <count group_id="O12" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="43"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="43"/>
                    <count group_id="O10" value="46"/>
                    <count group_id="O11" value="41"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.736" lower_limit="0.556" upper_limit="0.975"/>
                    <measurement group_id="O2" value="0.593" lower_limit="0.476" upper_limit="0.739"/>
                    <measurement group_id="O3" value="0.616" lower_limit="0.499" upper_limit="0.762"/>
                    <measurement group_id="O4" value="0.55" lower_limit="0.439" upper_limit="0.69"/>
                    <measurement group_id="O5" value="0.581" lower_limit="0.428" upper_limit="0.788"/>
                    <measurement group_id="O6" value="0.628" lower_limit="0.483" upper_limit="0.815"/>
                    <measurement group_id="O7" value="0.714" lower_limit="0.581" upper_limit="0.876"/>
                    <measurement group_id="O8" value="0.627" lower_limit="0.509" upper_limit="0.774"/>
                    <measurement group_id="O9" value="0.656" lower_limit="0.514" upper_limit="0.836"/>
                    <measurement group_id="O10" value="0.665" lower_limit="0.552" upper_limit="0.8"/>
                    <measurement group_id="O11" value="0.546" lower_limit="0.417" upper_limit="0.715"/>
                    <measurement group_id="O12" value="0.642" lower_limit="0.518" upper_limit="0.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="40"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.492" lower_limit="5.932" upper_limit="9.463"/>
                    <measurement group_id="O2" value="5.257" lower_limit="4.033" upper_limit="6.853"/>
                    <measurement group_id="O3" value="7.57" lower_limit="5.512" upper_limit="10.396"/>
                    <measurement group_id="O4" value="5.926" lower_limit="4.752" upper_limit="7.39"/>
                    <measurement group_id="O5" value="5.831" lower_limit="4.642" upper_limit="7.324"/>
                    <measurement group_id="O6" value="6.486" lower_limit="4.778" upper_limit="8.805"/>
                    <measurement group_id="O7" value="7.059" lower_limit="5.455" upper_limit="9.136"/>
                    <measurement group_id="O8" value="7.226" lower_limit="5.872" upper_limit="8.892"/>
                    <measurement group_id="O9" value="8.206" lower_limit="6.869" upper_limit="9.802"/>
                    <measurement group_id="O10" value="7.238" lower_limit="5.322" upper_limit="9.845"/>
                    <measurement group_id="O11" value="6.477" lower_limit="5.069" upper_limit="8.277"/>
                    <measurement group_id="O12" value="6.749" lower_limit="4.931" upper_limit="9.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="43"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="43"/>
                    <count group_id="O10" value="46"/>
                    <count group_id="O11" value="40"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.838" lower_limit="0.661" upper_limit="1.062"/>
                    <measurement group_id="O2" value="0.735" lower_limit="0.573" upper_limit="0.944"/>
                    <measurement group_id="O3" value="0.66" lower_limit="0.519" upper_limit="0.839"/>
                    <measurement group_id="O4" value="0.681" lower_limit="0.538" upper_limit="0.862"/>
                    <measurement group_id="O5" value="0.868" lower_limit="0.668" upper_limit="1.13"/>
                    <measurement group_id="O6" value="0.692" lower_limit="0.531" upper_limit="0.901"/>
                    <measurement group_id="O7" value="0.843" lower_limit="0.661" upper_limit="1.076"/>
                    <measurement group_id="O8" value="0.883" lower_limit="0.686" upper_limit="1.136"/>
                    <measurement group_id="O9" value="0.858" lower_limit="0.671" upper_limit="1.097"/>
                    <measurement group_id="O10" value="0.666" lower_limit="0.523" upper_limit="0.849"/>
                    <measurement group_id="O11" value="0.698" lower_limit="0.538" upper_limit="0.907"/>
                    <measurement group_id="O12" value="0.9" lower_limit="0.707" upper_limit="1.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="40"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.03" lower_limit="6.347" upper_limit="10.159"/>
                    <measurement group_id="O2" value="6.887" lower_limit="5.372" upper_limit="8.829"/>
                    <measurement group_id="O3" value="7.283" lower_limit="5.179" upper_limit="10.243"/>
                    <measurement group_id="O4" value="7.092" lower_limit="5.734" upper_limit="8.772"/>
                    <measurement group_id="O5" value="7.269" lower_limit="5.916" upper_limit="8.932"/>
                    <measurement group_id="O6" value="6.522" lower_limit="4.886" upper_limit="8.707"/>
                    <measurement group_id="O7" value="7.095" lower_limit="5.32" upper_limit="9.461"/>
                    <measurement group_id="O8" value="10.8" lower_limit="8.799" upper_limit="13.254"/>
                    <measurement group_id="O9" value="9.045" lower_limit="7.659" upper_limit="10.681"/>
                    <measurement group_id="O10" value="6.491" lower_limit="4.93" upper_limit="8.546"/>
                    <measurement group_id="O11" value="7.431" lower_limit="5.672" upper_limit="9.736"/>
                    <measurement group_id="O12" value="7.423" lower_limit="5.625" upper_limit="9.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)</title>
        <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL.</description>
        <time_frame>One month after primary immunization (Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)</title>
          <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="53.7" upper_limit="65.1"/>
                    <measurement group_id="O2" value="64.2" lower_limit="58.7" upper_limit="70.2"/>
                    <measurement group_id="O3" value="65" lower_limit="59.6" upper_limit="71"/>
                    <measurement group_id="O4" value="60.4" lower_limit="51.4" upper_limit="71"/>
                    <measurement group_id="O5" value="63.1" lower_limit="52" upper_limit="76.6"/>
                    <measurement group_id="O6" value="61.5" lower_limit="53.1" upper_limit="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="142"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.1" lower_limit="147.8" upper_limit="180.1"/>
                    <measurement group_id="O2" value="171.6" lower_limit="154.7" upper_limit="190.4"/>
                    <measurement group_id="O3" value="191.1" lower_limit="171.1" upper_limit="213.5"/>
                    <measurement group_id="O4" value="171" lower_limit="139.8" upper_limit="209.2"/>
                    <measurement group_id="O5" value="196.5" lower_limit="163.1" upper_limit="236.8"/>
                    <measurement group_id="O6" value="168.9" lower_limit="141.9" upper_limit="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.9" lower_limit="91.5" upper_limit="118"/>
                    <measurement group_id="O2" value="114.3" lower_limit="101" upper_limit="129.3"/>
                    <measurement group_id="O3" value="118.1" lower_limit="103.9" upper_limit="134.3"/>
                    <measurement group_id="O4" value="97.1" lower_limit="76.7" upper_limit="123.1"/>
                    <measurement group_id="O5" value="106.2" lower_limit="83.1" upper_limit="135.7"/>
                    <measurement group_id="O6" value="114" lower_limit="95.6" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)</title>
        <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)</title>
          <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="44"/>
                <count group_id="O10" value="49"/>
                <count group_id="O11" value="44"/>
                <count group_id="O12" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="43"/>
                    <count group_id="O10" value="45"/>
                    <count group_id="O11" value="38"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="10.8" upper_limit="16.3"/>
                    <measurement group_id="O2" value="12.8" lower_limit="11" upper_limit="14.9"/>
                    <measurement group_id="O3" value="10.5" lower_limit="8.2" upper_limit="13.3"/>
                    <measurement group_id="O4" value="14.7" lower_limit="11.1" upper_limit="19.6"/>
                    <measurement group_id="O5" value="14.2" lower_limit="11.4" upper_limit="17.8"/>
                    <measurement group_id="O6" value="13.6" lower_limit="11.1" upper_limit="16.7"/>
                    <measurement group_id="O7" value="12.8" lower_limit="9.9" upper_limit="16.7"/>
                    <measurement group_id="O8" value="12" lower_limit="9.1" upper_limit="15.9"/>
                    <measurement group_id="O9" value="15.2" lower_limit="12.4" upper_limit="18.5"/>
                    <measurement group_id="O10" value="13" lower_limit="10.6" upper_limit="16.1"/>
                    <measurement group_id="O11" value="10.8" lower_limit="8.6" upper_limit="13.7"/>
                    <measurement group_id="O12" value="14.2" lower_limit="10.5" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="43"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="40"/>
                    <count group_id="O10" value="46"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="58.9" upper_limit="92.5"/>
                    <measurement group_id="O2" value="64.4" lower_limit="50.4" upper_limit="82.3"/>
                    <measurement group_id="O3" value="56.6" lower_limit="39.9" upper_limit="80.5"/>
                    <measurement group_id="O4" value="72.3" lower_limit="57.7" upper_limit="90.6"/>
                    <measurement group_id="O5" value="75.5" lower_limit="59.4" upper_limit="95.9"/>
                    <measurement group_id="O6" value="74.8" lower_limit="56.9" upper_limit="98.2"/>
                    <measurement group_id="O7" value="63.4" lower_limit="48" upper_limit="83.6"/>
                    <measurement group_id="O8" value="74.9" lower_limit="60" upper_limit="93.4"/>
                    <measurement group_id="O9" value="97.6" lower_limit="82.5" upper_limit="115.5"/>
                    <measurement group_id="O10" value="59.4" lower_limit="46.8" upper_limit="75.2"/>
                    <measurement group_id="O11" value="66.8" lower_limit="50.6" upper_limit="88.3"/>
                    <measurement group_id="O12" value="57" lower_limit="42.2" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="38"/>
                    <count group_id="O9" value="42"/>
                    <count group_id="O10" value="45"/>
                    <count group_id="O11" value="38"/>
                    <count group_id="O12" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" lower_limit="36.7" upper_limit="57.9"/>
                    <measurement group_id="O2" value="42.6" lower_limit="34.5" upper_limit="52.6"/>
                    <measurement group_id="O3" value="42.6" lower_limit="33.3" upper_limit="54.5"/>
                    <measurement group_id="O4" value="53.8" lower_limit="40.2" upper_limit="72.2"/>
                    <measurement group_id="O5" value="59.3" lower_limit="44.1" upper_limit="79.8"/>
                    <measurement group_id="O6" value="57.7" lower_limit="41.7" upper_limit="79.9"/>
                    <measurement group_id="O7" value="57.9" lower_limit="42.5" upper_limit="78.8"/>
                    <measurement group_id="O8" value="45.7" lower_limit="36.3" upper_limit="57.6"/>
                    <measurement group_id="O9" value="59.1" lower_limit="46.4" upper_limit="75.1"/>
                    <measurement group_id="O10" value="50.8" lower_limit="42.1" upper_limit="61.3"/>
                    <measurement group_id="O11" value="48.5" lower_limit="39.7" upper_limit="59.3"/>
                    <measurement group_id="O12" value="52.9" lower_limit="39.1" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="43"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="40"/>
                    <count group_id="O10" value="46"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.8" lower_limit="247.1" upper_limit="385.9"/>
                    <measurement group_id="O2" value="252.7" lower_limit="195.1" upper_limit="327.4"/>
                    <measurement group_id="O3" value="327.2" lower_limit="240.9" upper_limit="444.4"/>
                    <measurement group_id="O4" value="359.8" lower_limit="289.2" upper_limit="447.6"/>
                    <measurement group_id="O5" value="322.9" lower_limit="252.2" upper_limit="413.4"/>
                    <measurement group_id="O6" value="332.7" lower_limit="250.9" upper_limit="441.2"/>
                    <measurement group_id="O7" value="312.3" lower_limit="238.7" upper_limit="408.8"/>
                    <measurement group_id="O8" value="338.6" lower_limit="270.3" upper_limit="424.3"/>
                    <measurement group_id="O9" value="442.8" lower_limit="370.6" upper_limit="529"/>
                    <measurement group_id="O10" value="321" lower_limit="246.5" upper_limit="417.9"/>
                    <measurement group_id="O11" value="332.9" lower_limit="258.2" upper_limit="429.3"/>
                    <measurement group_id="O12" value="294.2" lower_limit="224.3" upper_limit="385.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="44"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="42"/>
                    <count group_id="O12" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="11.8" upper_limit="21.1"/>
                    <measurement group_id="O2" value="16" lower_limit="12.9" upper_limit="19.9"/>
                    <measurement group_id="O3" value="18.3" lower_limit="13.8" upper_limit="24.4"/>
                    <measurement group_id="O4" value="22.4" lower_limit="16.5" upper_limit="30.5"/>
                    <measurement group_id="O5" value="25.1" lower_limit="18.5" upper_limit="34"/>
                    <measurement group_id="O6" value="16" lower_limit="11.6" upper_limit="22.1"/>
                    <measurement group_id="O7" value="19.4" lower_limit="13.5" upper_limit="27.9"/>
                    <measurement group_id="O8" value="18.8" lower_limit="14.1" upper_limit="24.9"/>
                    <measurement group_id="O9" value="27.3" lower_limit="20.9" upper_limit="35.7"/>
                    <measurement group_id="O10" value="20.1" lower_limit="14.7" upper_limit="27.6"/>
                    <measurement group_id="O11" value="19.7" lower_limit="14.6" upper_limit="26.7"/>
                    <measurement group_id="O12" value="20.3" lower_limit="14.3" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="40"/>
                    <count group_id="O10" value="49"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.6" lower_limit="162.4" upper_limit="294.3"/>
                    <measurement group_id="O2" value="173.5" lower_limit="131" upper_limit="229.8"/>
                    <measurement group_id="O3" value="225.9" lower_limit="145.9" upper_limit="349.8"/>
                    <measurement group_id="O4" value="262.9" lower_limit="196.5" upper_limit="351.7"/>
                    <measurement group_id="O5" value="246.2" lower_limit="182.5" upper_limit="332"/>
                    <measurement group_id="O6" value="184.3" lower_limit="122.6" upper_limit="277.1"/>
                    <measurement group_id="O7" value="226.7" lower_limit="162.6" upper_limit="316.1"/>
                    <measurement group_id="O8" value="255.7" lower_limit="189.9" upper_limit="344.3"/>
                    <measurement group_id="O9" value="330.4" lower_limit="263.9" upper_limit="413.7"/>
                    <measurement group_id="O10" value="205.1" lower_limit="148.5" upper_limit="283.5"/>
                    <measurement group_id="O11" value="214.2" lower_limit="151.8" upper_limit="302.3"/>
                    <measurement group_id="O12" value="213.6" lower_limit="151.2" upper_limit="301.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Hepatitis B Surface Antigen (HBs)</title>
        <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL.</description>
        <time_frame>One month after primary immunization (Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Hepatitis B Surface Antigen (HBs)</title>
          <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="911.85" lower_limit="719.55" upper_limit="1155.56"/>
                    <measurement group_id="O2" value="1139.1" lower_limit="902.93" upper_limit="1437.04"/>
                    <measurement group_id="O3" value="1245.07" lower_limit="998.97" upper_limit="1551.8"/>
                    <measurement group_id="O4" value="934.65" lower_limit="580.7" upper_limit="1504.32"/>
                    <measurement group_id="O5" value="674.25" lower_limit="373.26" upper_limit="1217.95"/>
                    <measurement group_id="O6" value="1027.79" lower_limit="719.24" upper_limit="1468.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Hepatitis B Surface Antigen</title>
        <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Hepatitis B Surface Antigen</title>
          <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="37"/>
                <count group_id="O11" value="37"/>
                <count group_id="O12" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HBs, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="36"/>
                    <count group_id="O10" value="33"/>
                    <count group_id="O11" value="33"/>
                    <count group_id="O12" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.46" lower_limit="125.7" upper_limit="310.18"/>
                    <measurement group_id="O2" value="210.32" lower_limit="125.47" upper_limit="352.56"/>
                    <measurement group_id="O3" value="164.33" lower_limit="98.38" upper_limit="274.49"/>
                    <measurement group_id="O4" value="136.53" lower_limit="77.08" upper_limit="241.83"/>
                    <measurement group_id="O5" value="225.01" lower_limit="135.08" upper_limit="374.83"/>
                    <measurement group_id="O6" value="194.51" lower_limit="128.13" upper_limit="295.29"/>
                    <measurement group_id="O7" value="226.1" lower_limit="134.4" upper_limit="380.39"/>
                    <measurement group_id="O8" value="244.52" lower_limit="133.36" upper_limit="448.35"/>
                    <measurement group_id="O9" value="159.79" lower_limit="96.78" upper_limit="263.8"/>
                    <measurement group_id="O10" value="128.12" lower_limit="78.68" upper_limit="208.6"/>
                    <measurement group_id="O11" value="199.57" lower_limit="115.04" upper_limit="346.22"/>
                    <measurement group_id="O12" value="209.27" lower_limit="121.25" upper_limit="361.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="37"/>
                    <count group_id="O9" value="40"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="37"/>
                    <count group_id="O12" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1949.42" lower_limit="1220.13" upper_limit="3114.61"/>
                    <measurement group_id="O2" value="1898.54" lower_limit="1147.47" upper_limit="3141.21"/>
                    <measurement group_id="O3" value="1970.6" lower_limit="1017.24" upper_limit="3817.44"/>
                    <measurement group_id="O4" value="1685.87" lower_limit="1012.93" upper_limit="2805.87"/>
                    <measurement group_id="O5" value="2492.42" lower_limit="1638.97" upper_limit="3790.27"/>
                    <measurement group_id="O6" value="2107.75" lower_limit="1257.97" upper_limit="3531.56"/>
                    <measurement group_id="O7" value="1851.22" lower_limit="1033.84" upper_limit="3314.85"/>
                    <measurement group_id="O8" value="2579.59" lower_limit="1575.91" upper_limit="4222.52"/>
                    <measurement group_id="O9" value="3244.33" lower_limit="2235.34" upper_limit="4708.75"/>
                    <measurement group_id="O10" value="2078.63" lower_limit="1261.91" upper_limit="3423.92"/>
                    <measurement group_id="O11" value="2003.09" lower_limit="1040.72" upper_limit="3855.37"/>
                    <measurement group_id="O12" value="2218.23" lower_limit="1219.17" upper_limit="4035.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)</title>
        <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL.</description>
        <time_frame>One month after primary immunization (Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)</title>
          <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.994" lower_limit="3.268" upper_limit="4.882"/>
                    <measurement group_id="O2" value="3.66" lower_limit="3.073" upper_limit="4.359"/>
                    <measurement group_id="O3" value="4.51" lower_limit="3.753" upper_limit="5.419"/>
                    <measurement group_id="O4" value="3.29" lower_limit="2.362" upper_limit="4.583"/>
                    <measurement group_id="O5" value="4.23" lower_limit="3.025" upper_limit="5.914"/>
                    <measurement group_id="O6" value="5.007" lower_limit="3.69" upper_limit="6.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)</title>
        <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in µg/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)</title>
          <description>Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in µg/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="44"/>
                <count group_id="O10" value="47"/>
                <count group_id="O11" value="44"/>
                <count group_id="O12" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="44"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="43"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="46"/>
                    <count group_id="O11" value="42"/>
                    <count group_id="O12" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.878" lower_limit="0.609" upper_limit="1.266"/>
                    <measurement group_id="O2" value="0.684" lower_limit="0.48" upper_limit="0.974"/>
                    <measurement group_id="O3" value="0.678" lower_limit="0.436" upper_limit="1.055"/>
                    <measurement group_id="O4" value="0.824" lower_limit="0.554" upper_limit="1.226"/>
                    <measurement group_id="O5" value="0.847" lower_limit="0.571" upper_limit="1.256"/>
                    <measurement group_id="O6" value="0.763" lower_limit="0.51" upper_limit="1.141"/>
                    <measurement group_id="O7" value="0.798" lower_limit="0.518" upper_limit="1.231"/>
                    <measurement group_id="O8" value="0.72" lower_limit="0.531" upper_limit="0.977"/>
                    <measurement group_id="O9" value="1.013" lower_limit="0.689" upper_limit="1.491"/>
                    <measurement group_id="O10" value="0.696" lower_limit="0.5" upper_limit="0.967"/>
                    <measurement group_id="O11" value="0.651" lower_limit="0.452" upper_limit="0.938"/>
                    <measurement group_id="O12" value="0.953" lower_limit="0.655" upper_limit="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="47"/>
                    <count group_id="O11" value="44"/>
                    <count group_id="O12" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.964" lower_limit="15.76" upper_limit="30.61"/>
                    <measurement group_id="O2" value="17.484" lower_limit="11.592" upper_limit="26.37"/>
                    <measurement group_id="O3" value="21.277" lower_limit="12.268" upper_limit="36.901"/>
                    <measurement group_id="O4" value="20.28" lower_limit="13.96" upper_limit="29.462"/>
                    <measurement group_id="O5" value="18.987" lower_limit="13.365" upper_limit="26.973"/>
                    <measurement group_id="O6" value="17.544" lower_limit="11.966" upper_limit="25.722"/>
                    <measurement group_id="O7" value="20.659" lower_limit="14.948" upper_limit="28.55"/>
                    <measurement group_id="O8" value="33.45" lower_limit="23.717" upper_limit="47.176"/>
                    <measurement group_id="O9" value="22.083" lower_limit="14.795" upper_limit="32.961"/>
                    <measurement group_id="O10" value="16.682" lower_limit="11.367" upper_limit="24.481"/>
                    <measurement group_id="O11" value="21.602" lower_limit="14.406" upper_limit="32.392"/>
                    <measurement group_id="O12" value="23.277" lower_limit="16.047" upper_limit="33.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers Against Poliovirus Type 1, 2 and 3</title>
        <description>Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8.</description>
        <time_frame>One month after primary immunization (Month 3)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
          </group>
          <group group_id="O2">
            <title>DIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O3">
            <title>NIBU Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O4">
            <title>IPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O5">
            <title>DPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
          <group group_id="O6">
            <title>NPARA Group</title>
            <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against Poliovirus Type 1, 2 and 3</title>
          <description>Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.4" lower_limit="175.5" upper_limit="457.6"/>
                    <measurement group_id="O2" value="252.5" lower_limit="156.9" upper_limit="406.2"/>
                    <measurement group_id="O3" value="337" lower_limit="204.2" upper_limit="556.2"/>
                    <measurement group_id="O4" value="225.6" lower_limit="103.2" upper_limit="492.8"/>
                    <measurement group_id="O5" value="166" lower_limit="97.9" upper_limit="281.4"/>
                    <measurement group_id="O6" value="449.3" lower_limit="127.6" upper_limit="1581.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362" lower_limit="259.1" upper_limit="505.9"/>
                    <measurement group_id="O2" value="327.4" lower_limit="196.8" upper_limit="544.8"/>
                    <measurement group_id="O3" value="378" lower_limit="234.9" upper_limit="608.1"/>
                    <measurement group_id="O4" value="240.7" lower_limit="121.9" upper_limit="475.3"/>
                    <measurement group_id="O5" value="394.8" lower_limit="99.5" upper_limit="1567.1"/>
                    <measurement group_id="O6" value="335.2" lower_limit="152.8" upper_limit="735.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423.2" lower_limit="255.2" upper_limit="701.9"/>
                    <measurement group_id="O2" value="351.3" lower_limit="236.4" upper_limit="522.1"/>
                    <measurement group_id="O3" value="624.1" lower_limit="394.5" upper_limit="987.4"/>
                    <measurement group_id="O4" value="284" lower_limit="151.3" upper_limit="533.3"/>
                    <measurement group_id="O5" value="394.8" lower_limit="153.9" upper_limit="1012.5"/>
                    <measurement group_id="O6" value="438.6" lower_limit="142.5" upper_limit="1349.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers Against Poliovirus Type 1, 2 and 3</title>
        <description>Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8.</description>
        <time_frame>Prior to (Month 9) and one month after booster vaccination (Month 10)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
        <group_list>
          <group group_id="O1">
            <title>IIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O2">
            <title>IIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O3">
            <title>IIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O4">
            <title>DIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O5">
            <title>DIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O6">
            <title>DIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O7">
            <title>NIBU-IIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O8">
            <title>NIBU-DIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O9">
            <title>NIBU-NIBU Group</title>
            <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O10">
            <title>IPARA-NPARA Group</title>
            <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O11">
            <title>DPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
          <group group_id="O12">
            <title>NPARA-IPARA Group</title>
            <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against Poliovirus Type 1, 2 and 3</title>
          <description>Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="15.7" upper_limit="200.2"/>
                    <measurement group_id="O2" value="85.9" lower_limit="26.7" upper_limit="276.4"/>
                    <measurement group_id="O3" value="80.9" lower_limit="18.7" upper_limit="349.8"/>
                    <measurement group_id="O4" value="145.7" lower_limit="59.8" upper_limit="354.5"/>
                    <measurement group_id="O5" value="45.4" lower_limit="15.9" upper_limit="129.6"/>
                    <measurement group_id="O6" value="32.1" lower_limit="11.8" upper_limit="87.3"/>
                    <measurement group_id="O7" value="67.1" lower_limit="12.9" upper_limit="348.4"/>
                    <measurement group_id="O8" value="53.7" lower_limit="2.7" upper_limit="1083.7"/>
                    <measurement group_id="O9" value="141.2" lower_limit="54.2" upper_limit="368"/>
                    <measurement group_id="O10" value="53.8" lower_limit="12.5" upper_limit="232"/>
                    <measurement group_id="O11" value="128.3" lower_limit="8.4" upper_limit="1971.9"/>
                    <measurement group_id="O12" value="117.4" lower_limit="12.7" upper_limit="1084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1378.2" lower_limit="682.4" upper_limit="2783.4"/>
                    <measurement group_id="O2" value="790.7" lower_limit="75.3" upper_limit="8304.9"/>
                    <measurement group_id="O3" value="429.9" lower_limit="35.6" upper_limit="5190.7"/>
                    <measurement group_id="O4" value="1824.5" lower_limit="831.6" upper_limit="4003"/>
                    <measurement group_id="O5" value="388" lower_limit="60.4" upper_limit="2494.6"/>
                    <measurement group_id="O6" value="543.9" lower_limit="79.4" upper_limit="3726.3"/>
                    <measurement group_id="O7" value="1217.7" lower_limit="327.7" upper_limit="4525.4"/>
                    <measurement group_id="O8" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O9" value="1075.9" lower_limit="546.1" upper_limit="2119.8"/>
                    <measurement group_id="O10" value="1290.1" lower_limit="455.8" upper_limit="3651.2"/>
                    <measurement group_id="O11" value="1448.1" lower_limit="148.5" upper_limit="14125.5"/>
                    <measurement group_id="O12" value="861.1" lower_limit="74.6" upper_limit="9935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.8" lower_limit="27" upper_limit="540.4"/>
                    <measurement group_id="O2" value="60.8" lower_limit="17.8" upper_limit="207"/>
                    <measurement group_id="O3" value="48.3" lower_limit="16.3" upper_limit="143.4"/>
                    <measurement group_id="O4" value="292.1" lower_limit="61.3" upper_limit="1391.9"/>
                    <measurement group_id="O5" value="41.7" lower_limit="19.6" upper_limit="88.5"/>
                    <measurement group_id="O6" value="8" lower_limit="0" upper_limit="53461.2"/>
                    <measurement group_id="O7" value="134.8" lower_limit="54.1" upper_limit="336.1"/>
                    <measurement group_id="O8" value="119.6" lower_limit="25.8" upper_limit="553.9"/>
                    <measurement group_id="O9" value="156.1" lower_limit="65.7" upper_limit="371"/>
                    <measurement group_id="O10" value="29.7" lower_limit="10.5" upper_limit="83.9"/>
                    <measurement group_id="O11" value="139.6" lower_limit="106" upper_limit="183.9"/>
                    <measurement group_id="O12" value="168.9" lower_limit="73.8" upper_limit="386.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="9"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1949" lower_limit="844.4" upper_limit="4498.6"/>
                    <measurement group_id="O2" value="1217.7" lower_limit="101.3" upper_limit="14638.5"/>
                    <measurement group_id="O3" value="548.7" lower_limit="41.2" upper_limit="7308"/>
                    <measurement group_id="O4" value="2151.9" lower_limit="715.2" upper_limit="6474.4"/>
                    <measurement group_id="O5" value="512.5" lower_limit="131.8" upper_limit="1993.2"/>
                    <measurement group_id="O6" value="542.4" lower_limit="41.7" upper_limit="7057.5"/>
                    <measurement group_id="O7" value="1217.7" lower_limit="195.5" upper_limit="7583"/>
                    <measurement group_id="O8" value="434.1" lower_limit="0" upper_limit="999999"/>
                    <measurement group_id="O9" value="1393.4" lower_limit="731.1" upper_limit="2655.7"/>
                    <measurement group_id="O10" value="2047.9" lower_limit="1068.3" upper_limit="3925.7"/>
                    <measurement group_id="O11" value="1625.4" lower_limit="270.8" upper_limit="9756.8"/>
                    <measurement group_id="O12" value="1116.6" lower_limit="126.6" upper_limit="9848.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="18.9" upper_limit="273.5"/>
                    <measurement group_id="O2" value="86" lower_limit="33.8" upper_limit="218.9"/>
                    <measurement group_id="O3" value="127.8" lower_limit="30.6" upper_limit="534.2"/>
                    <measurement group_id="O4" value="205.4" lower_limit="52.5" upper_limit="804.1"/>
                    <measurement group_id="O5" value="45.3" lower_limit="14.2" upper_limit="144.4"/>
                    <measurement group_id="O6" value="45.2" lower_limit="19.1" upper_limit="106.8"/>
                    <measurement group_id="O7" value="70" lower_limit="31.6" upper_limit="155.4"/>
                    <measurement group_id="O8" value="139.6" lower_limit="30.5" upper_limit="638.7"/>
                    <measurement group_id="O9" value="128" lower_limit="75.8" upper_limit="216.3"/>
                    <measurement group_id="O10" value="96.5" lower_limit="12.3" upper_limit="758.1"/>
                    <measurement group_id="O11" value="108.1" lower_limit="62.5" upper_limit="186.8"/>
                    <measurement group_id="O12" value="69.7" lower_limit="2.2" upper_limit="2175.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="8"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="861" lower_limit="363.5" upper_limit="2039.4"/>
                    <measurement group_id="O2" value="1724.5" lower_limit="66.3" upper_limit="44854.5"/>
                    <measurement group_id="O3" value="359.5" lower_limit="8.4" upper_limit="15474.7"/>
                    <measurement group_id="O4" value="3649.1" lower_limit="1721.5" upper_limit="7735.1"/>
                    <measurement group_id="O5" value="588.1" lower_limit="44" upper_limit="7860.3"/>
                    <measurement group_id="O6" value="1152.5" lower_limit="123.7" upper_limit="10737.5"/>
                    <measurement group_id="O7" value="558.3" lower_limit="140.6" upper_limit="2216.3"/>
                    <measurement group_id="O8" value="724.1" lower_limit="0" upper_limit="999999"/>
                    <measurement group_id="O9" value="2233.3" lower_limit="1122.1" upper_limit="4445"/>
                    <measurement group_id="O10" value="2195" lower_limit="889" upper_limit="5419.4"/>
                    <measurement group_id="O11" value="1625.4" lower_limit="436.4" upper_limit="6054.1"/>
                    <measurement group_id="O12" value="2048" lower_limit="2048" upper_limit="2048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local/general symptoms: during the 4-day (Days 0-3) follow-up periods after primary and booster vaccination. Unsolicited AEs: during the 31-day (Days 0-30) follow-up periods after primary and booster vaccination. SAEs: during the entire study period (from Month 0 up to Month 10).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate ibuprofen (IIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for Serious Adverse Event (SAE) follow-up for the entire study period.</description>
        </group>
        <group group_id="E2">
          <title>DIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed ibuprofen (DIBU) administration with Nurofen™ for Children after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="E3">
          <title>NIBU Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic ibuprofen (NIBU) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="E4">
          <title>IPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received immediate paracetamol (IPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="E5">
          <title>DPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received delayed paracetamol (DPARA) administration with Panadol™ Baby after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. For delayed oral administration of Panadol™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="E6">
          <title>NPARA Group</title>
          <description>Healthy male and female subjects between and including 12 and 16 weeks of age, who received no prophylactic paracetamol (NPARA) administration after each primary vaccination dose of Synflorix™ vaccine at 3, 4 and 5 months of age, co-administered with Infanrix hexa™ at 3 and 5 months of age and with Infanrix™-IPV/Hib at 4 months of age. All three vaccines were administered intramuscularly into the right or left thigh. This group is applicable for all analysis related to the primary phase of the study as well as for SAE follow-up for the entire study period.</description>
        </group>
        <group group_id="E7">
          <title>IIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipryretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E8">
          <title>IIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E9">
          <title>IIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Immediate Ibuprofen Group (IIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E10">
          <title>DIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E11">
          <title>DIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E12">
          <title>DIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/Delayed Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E13">
          <title>NIBU-IIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (NIBU Group) received immediate ibuprofen treatment (IIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Nurofen™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E14">
          <title>NIBU-DIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received delayed ibuprofen treatment (DIBU) with Nurofen™ for Children after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For delayed oral administration of Nurofen™: antipyretic dose 1 was administered 4-6 hours after vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E15">
          <title>NIBU-NIBU Group</title>
          <description>1/3 of the subjects from the primary Synflorix/No Ibuprofen Group (DIBU Group) received no prophylactic ibuprofen treatment (NIBU) with Nurofen™ for Children after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E16">
          <title>IPARA-NPARA Group</title>
          <description>Subjects from the primary Synflorix/Immediate Paracetamol Group (IPARA Group) received no prophylactic paracetamol treatment (NPARA) with Panadol™ Baby after the booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E17">
          <title>DPARA-IPARA Group</title>
          <description>Subjects from the primary Synflorix/Delayed Paracetamol Group (DPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
        <group group_id="E18">
          <title>NPARA-IPARA Group</title>
          <description>Subjects from the primary Synflorix/No Paracetamol Group (NPARA Group) received immediate paracetamol treatment (IPARA) with Panadol™ Baby after booster vaccination with Synflorix™ vaccine co-administered with Infanrix hexa™ vaccine at 12-15 months of age. For immediate oral administration of Panadol™: antipyretic dose 1 was administered at the time of vaccination, antipyretic doses 2 and 3 were administered 6-8 hours after the previous dose of antipyretic. Both vaccines were administered intramuscularly into the right/left thigh or into the deltoid muscle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rickets</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="186" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="44" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="34" subjects_at_risk="63"/>
                <counts group_id="E10" subjects_affected="43" subjects_at_risk="63"/>
                <counts group_id="E11" subjects_affected="41" subjects_at_risk="63"/>
                <counts group_id="E12" subjects_affected="42" subjects_at_risk="63"/>
                <counts group_id="E13" subjects_affected="50" subjects_at_risk="63"/>
                <counts group_id="E14" subjects_affected="51" subjects_at_risk="65"/>
                <counts group_id="E15" subjects_affected="45" subjects_at_risk="62"/>
                <counts group_id="E16" subjects_affected="43" subjects_at_risk="67"/>
                <counts group_id="E17" subjects_affected="45" subjects_at_risk="68"/>
                <counts group_id="E18" subjects_affected="45" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="154" subjects_affected="92" subjects_at_risk="198"/>
                <counts group_id="E2" events="145" subjects_affected="76" subjects_at_risk="198"/>
                <counts group_id="E3" events="197" subjects_affected="107" subjects_at_risk="199"/>
                <counts group_id="E4" events="58" subjects_affected="30" subjects_at_risk="71"/>
                <counts group_id="E5" events="71" subjects_affected="37" subjects_at_risk="72"/>
                <counts group_id="E6" events="80" subjects_affected="44" subjects_at_risk="74"/>
                <counts group_id="E7" events="25" subjects_affected="25" subjects_at_risk="64"/>
                <counts group_id="E8" events="22" subjects_affected="22" subjects_at_risk="60"/>
                <counts group_id="E9" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E10" events="22" subjects_affected="22" subjects_at_risk="63"/>
                <counts group_id="E11" events="16" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E12" events="25" subjects_affected="25" subjects_at_risk="63"/>
                <counts group_id="E13" events="28" subjects_affected="28" subjects_at_risk="63"/>
                <counts group_id="E14" events="32" subjects_affected="32" subjects_at_risk="65"/>
                <counts group_id="E15" events="28" subjects_affected="28" subjects_at_risk="62"/>
                <counts group_id="E16" events="23" subjects_affected="23" subjects_at_risk="67"/>
                <counts group_id="E17" events="24" subjects_affected="24" subjects_at_risk="68"/>
                <counts group_id="E18" events="24" subjects_affected="24" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="205" subjects_affected="121" subjects_at_risk="198"/>
                <counts group_id="E2" events="165" subjects_affected="102" subjects_at_risk="198"/>
                <counts group_id="E3" events="200" subjects_affected="123" subjects_at_risk="199"/>
                <counts group_id="E4" events="35" subjects_affected="23" subjects_at_risk="71"/>
                <counts group_id="E5" events="35" subjects_affected="28" subjects_at_risk="72"/>
                <counts group_id="E6" events="68" subjects_affected="40" subjects_at_risk="74"/>
                <counts group_id="E7" events="22" subjects_affected="22" subjects_at_risk="64"/>
                <counts group_id="E8" events="21" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E9" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E10" events="19" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E11" events="19" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E12" events="20" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E13" events="20" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E14" events="23" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E15" events="28" subjects_affected="28" subjects_at_risk="62"/>
                <counts group_id="E16" events="21" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E17" events="14" subjects_affected="14" subjects_at_risk="68"/>
                <counts group_id="E18" events="18" subjects_affected="18" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="96" subjects_affected="61" subjects_at_risk="198"/>
                <counts group_id="E2" events="87" subjects_affected="51" subjects_at_risk="198"/>
                <counts group_id="E3" events="89" subjects_affected="57" subjects_at_risk="199"/>
                <counts group_id="E4" events="36" subjects_affected="20" subjects_at_risk="71"/>
                <counts group_id="E5" events="30" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E6" events="36" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E7" events="16" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E8" events="16" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E10" events="16" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E12" events="11" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E13" events="16" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E14" events="18" subjects_affected="18" subjects_at_risk="65"/>
                <counts group_id="E15" events="15" subjects_affected="15" subjects_at_risk="62"/>
                <counts group_id="E16" events="17" subjects_affected="17" subjects_at_risk="67"/>
                <counts group_id="E17" events="12" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E18" events="16" subjects_affected="16" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="145" subjects_affected="84" subjects_at_risk="198"/>
                <counts group_id="E2" events="150" subjects_affected="98" subjects_at_risk="198"/>
                <counts group_id="E3" events="160" subjects_affected="100" subjects_at_risk="199"/>
                <counts group_id="E4" events="33" subjects_affected="25" subjects_at_risk="71"/>
                <counts group_id="E5" events="39" subjects_affected="24" subjects_at_risk="72"/>
                <counts group_id="E6" events="70" subjects_affected="42" subjects_at_risk="74"/>
                <counts group_id="E7" events="14" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E8" events="16" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E10" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E11" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E12" events="19" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E13" events="21" subjects_affected="21" subjects_at_risk="63"/>
                <counts group_id="E14" events="24" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E15" events="14" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E16" events="9" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E17" events="10" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E18" events="17" subjects_affected="17" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="197" subjects_affected="115" subjects_at_risk="198"/>
                <counts group_id="E2" events="194" subjects_affected="111" subjects_at_risk="198"/>
                <counts group_id="E3" events="209" subjects_affected="123" subjects_at_risk="199"/>
                <counts group_id="E4" events="79" subjects_affected="40" subjects_at_risk="71"/>
                <counts group_id="E5" events="51" subjects_affected="33" subjects_at_risk="72"/>
                <counts group_id="E6" events="77" subjects_affected="45" subjects_at_risk="74"/>
                <counts group_id="E7" events="18" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E8" events="18" subjects_affected="18" subjects_at_risk="60"/>
                <counts group_id="E9" events="17" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E10" events="19" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E11" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E12" events="21" subjects_affected="21" subjects_at_risk="63"/>
                <counts group_id="E13" events="22" subjects_affected="22" subjects_at_risk="63"/>
                <counts group_id="E14" events="24" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E15" events="24" subjects_affected="24" subjects_at_risk="62"/>
                <counts group_id="E16" events="12" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E17" events="16" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E18" events="19" subjects_affected="19" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="244" subjects_affected="120" subjects_at_risk="198"/>
                <counts group_id="E2" events="239" subjects_affected="121" subjects_at_risk="198"/>
                <counts group_id="E3" events="275" subjects_affected="138" subjects_at_risk="199"/>
                <counts group_id="E4" events="75" subjects_affected="41" subjects_at_risk="71"/>
                <counts group_id="E5" events="86" subjects_affected="43" subjects_at_risk="72"/>
                <counts group_id="E6" events="109" subjects_affected="59" subjects_at_risk="74"/>
                <counts group_id="E7" events="33" subjects_affected="33" subjects_at_risk="64"/>
                <counts group_id="E8" events="27" subjects_affected="27" subjects_at_risk="60"/>
                <counts group_id="E9" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E10" events="22" subjects_affected="22" subjects_at_risk="63"/>
                <counts group_id="E11" events="26" subjects_affected="26" subjects_at_risk="63"/>
                <counts group_id="E12" events="27" subjects_affected="27" subjects_at_risk="63"/>
                <counts group_id="E13" events="36" subjects_affected="36" subjects_at_risk="63"/>
                <counts group_id="E14" events="33" subjects_affected="33" subjects_at_risk="65"/>
                <counts group_id="E15" events="32" subjects_affected="32" subjects_at_risk="62"/>
                <counts group_id="E16" events="26" subjects_affected="26" subjects_at_risk="67"/>
                <counts group_id="E17" events="22" subjects_affected="22" subjects_at_risk="68"/>
                <counts group_id="E18" events="27" subjects_affected="27" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="217" subjects_affected="108" subjects_at_risk="198"/>
                <counts group_id="E2" events="174" subjects_affected="89" subjects_at_risk="198"/>
                <counts group_id="E3" events="205" subjects_affected="105" subjects_at_risk="199"/>
                <counts group_id="E4" events="76" subjects_affected="36" subjects_at_risk="71"/>
                <counts group_id="E5" events="67" subjects_affected="35" subjects_at_risk="72"/>
                <counts group_id="E6" events="90" subjects_affected="46" subjects_at_risk="74"/>
                <counts group_id="E7" events="27" subjects_affected="27" subjects_at_risk="64"/>
                <counts group_id="E8" events="25" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E9" events="17" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E10" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E11" events="15" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E12" events="22" subjects_affected="22" subjects_at_risk="63"/>
                <counts group_id="E13" events="23" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E14" events="25" subjects_affected="25" subjects_at_risk="65"/>
                <counts group_id="E15" events="23" subjects_affected="23" subjects_at_risk="62"/>
                <counts group_id="E16" events="23" subjects_affected="23" subjects_at_risk="67"/>
                <counts group_id="E17" events="23" subjects_affected="23" subjects_at_risk="68"/>
                <counts group_id="E18" events="23" subjects_affected="23" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

